| Q129587913 | 1 Obligatory tumour heterogeneity driven by Myc overexpression: mechanistic insights and therapeutic strategies |
| Q129589472 | 10 Extracellular vesicles that carry signalling networks drive phenocopying of migratory behaviour between cancer cells in vivo |
| Q113874543 | 11 ESMO 2021 breakthroughs: practicing oncologist’s perceptions on data presentation |
| Q129589467 | 11 The heterogeneous genomic and immune landscapes of lethal metastatic breast cancer |
| Q129588851 | 13 Exploring mechanisms of tumour lymphangiogenesis to potentiate immunotherapies in melanoma |
| Q129585850 | 14 A patient derived antibody targeting the tetraspanin CD9 inhibits tumour progression and metastasis |
| Q129588971 | 15 Identification of new combination therapies for lung cancer tumours harbouring KRAS mutations |
| Q129586562 | 16 Quadruple vertical targeting of an oncogenic pathway as a treatment strategy to prevent drug resistance |
| Q129585607 | 17 Quantifying microenvironmental signatures of oesophageal carcinogenesis |
| Q129586824 | 18 Eosinophils are an integral part of the tumour microenvironment in colorectal cancer exerting potent anti-tumorigenic activities |
| Q129588656 | 19 Autophagy induction as a new therapy for HER2+ breast tumorigenesis |
| Q123122409 | 19P Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study |
| Q129586684 | 20 Identification of combinatorial therapies with inhibitors of the PI3K pathway in PTEN-null tumours |
| Q94425077 | 2017 Thank you to our reviewers |
| Q55715100 | 2018 ESMO Sarcoma and GIST Symposium: 'take-home messages' in soft tissue sarcoma. |
| Q130190632 | 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting |
| Q129585834 | 21 Defining the cell populations responsible for skin cancer initiation and relapse following therapy |
| Q129588476 | 22 Luminal progenitor cells as a new target in castration-resistant prostate cancer (CRPC) |
| Q92024363 | 223-Radium for metastatic osteosarcoma: combination therapy with other agents and external beam radiotherapy |
| Q129673982 | 22P PD-L1 testing in mTNBC: Interplatform and interobserver reproducibility of CE-IVD assays for CPS and IC scores |
| Q129587633 | 23 Evidence for antigen-driven TCRB chain convergence in the tumourinfiltrating t cell repertoire of 148 research subjects with melanoma |
| Q129578394 | 23P Prognostic value of tumor-infiltrating lymphocytes (TILs) and soluble immune checkpoints in early triple-negative breast cancer (TNBC) |
| Q129662653 | 24P Associating BRCA1 hypermethylation with clinicopathological and molecular variables in triple-negative breast cancer |
| Q129586850 | 25 Strategies to overcome phenotype switch-driven therapy resistance in melanoma |
| Q129587367 | 26 Overcoming the limitations of lung cancer radiotherapy by targeting the CD73/adenosine immune checkpoint |
| Q123123220 | 263P Cross-sectional nationwide population-based study of living conditions, and identification of sexual and fertility profiles among young women after breast cancer in France: A study of the French Network of Cancer Registries (FRANCIM) |
| Q123123763 | 265P UCATS: A national specialist service for integration of gender affirming and oncological care in transgender patients with breast cancer |
| Q129586658 | 27 Visualise cancer cell dynamics of colorectal cancer progressionhj snippertsa rosenberg |
| Q129588035 | 28 Stress signalling in breast cancer cells induces matrix components of stem cell niches that promote chemotherapy-resistant metastasis |
| Q129586750 | 29 Radiation promotes transdifferentiation of glioblastoma stem cells into vascular cell types |
| Q129589427 | 3 Clonal dynamics of colon carcinoma progression |
| Q55278891 | 30 Immunotherapy in advanced NSCLC—from the ‘tsunami’ of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). |
| Q123002829 | 30 Whole-genome sequencing of normal stem cells provides novel insights into human native hematopoiesis and leukaemia aetiology |
| Q129587540 | 31 Loss of P53 drives systemic neutrophilic inflammation in breast cancer |
| Q115672128 | 32 Impact of colibactin-producing escherichia coli on immune microenvironment in preclinical colorectal cancer models |
| Q129587970 | 33 PAN-cancer whole genome sequencing reveals patterns of subclonal mutations, signature changes and selection |
| Q129589064 | 34 Gene fusions in 1,015 human cancer cell lines: integrating large-scale genomic data, high-throughput drug and CRISPR/Cas9 screens to assess functional relevance and therapeutic potential |
| Q129588145 | 4 Patterns of clustered mutational processes: Pan-Cancer analysis of chromothripsis, chromoplexy and kataegis |
| Q129587020 | 5 PIK3c2G loss promotes pancreatic cancer through MTOR regulation and metabolic rewiring |
| Q129588540 | 6 Imaging tumour metabolism to guide treatment of breast cancer with drugs targeted at PI3K alpha |
| Q123227107 | 61P The cysteine-rich protein 61 (Cyr61) contributes to tumor proliferation and invasion via HGF-mediated NF-kB signaling pathway in human hepatocellular carcinoma |
| Q129586646 | 7 Evolution of cross-resistance to CD8+ T cells in the course of BRAF and MEK inhibitor treatment in BRAFV600E melanoma |
| Q129588753 | 9 Liquid biopsy in small cell lung cancer (SCLC) |
| Q100394568 | A European survey on the insights of patients living with metastatic colorectal cancer: the patient journey before, during and after diagnosis - an Eastern European perspective |
| Q104745956 | A clinical validation study of MammaPrint in hormone receptor-positive breast cancer from the Austrian Breast and Colorectal Cancer Study Group 8 (ABCSG-8) biomarker cohort |
| Q55030434 | A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. |
| Q55025199 | A new era of oncology through artificial intelligence. |
| Q127174881 | A new schedule of one week on/one week off temozolomide as second-line treatment of advanced neuroendocrine carcinomas (TENEC-TRIAL): a multicenter, open-label, single-arm, phase II trial |
| Q92684907 | A phase Ib/II study of HER3-targeting lumretuzumab in combination with carboplatin and paclitaxel as first-line treatment in patients with advanced or metastatic squamous non-small cell lung cancer |
| Q54837286 | A prospective clinical trial to assess lapatinib effects on cutaneous squamous cell carcinoma and actinic keratosis. |
| Q53978383 | AIOM chooses ESMO Open-Cancer Horizons as its official journal: a warm welcome from ESMO Open. |
| Q58732118 | ALK IHC and FISH discordant results in patients with NSCLC and treatment response: for discussion of the question-to treat or not to treat? |
| Q54857752 | ASCO highlights podcast: head and neck cancers. |
| Q88646720 | ASCO: practice changing studies in gastrointestinal cancer |
| Q55009905 | Abiraterone: moving up in line? |
| Q91673669 | Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries |
| Q54986604 | Activating HER2 mutations as emerging targets in multiple solid cancers. |
| Q90603828 | Acute kidney injury from contrast-enhanced CT procedures in patients with cancer: white paper to highlight its clinical relevance and discuss applicable preventive strategies |
| Q102151746 | Addition of nivolumab to chemotherapy in patients with advanced gastric cancer: a relevant step ahead, but still many questions to answer |
| Q96949659 | Adjuvant and neoadjuvant therapies in melanoma |
| Q55064633 | Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy? |
| Q55647987 | Admission of critically ill patients with cancer to the ICU: many uncertainties remain. |
| Q92980890 | Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine |
| Q59333303 | All change: closing the gender gap in oncology |
| Q102151744 | An evaluation of self-perceived knowledge, attitudes and behaviours of UK oncologists about LGBTQ+ patients with cancer |
| Q92090909 | Announcing the ESMO Open special issue on upcoming molecular targets for cancer treatment |
| Q55072300 | Anti-PD-1/anti-PD-L1 immunotherapy versus docetaxel for previously treated advanced non-small cell lung cancer: a systematic review and meta-analysis of randomised clinical trials. |
| Q55364590 | Antithrombotic therapy for prophylaxis and treatment of venous thromboembolism in patients with cancer: review of the literature on current practice and emerging options. |
| Q99204236 | Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies |
| Q55026606 | Applying the ESMO-Magnitude of Clinical Benefit Scale in real life. |
| Q112701357 | Artificial intelligence for detection of microsatellite instability in colorectal cancer-a multicentric analysis of a pre-screening tool for clinical application |
| Q92972185 | Assessing molecular subtypes of gastric cancer: microsatellite unstable and Epstein-Barr virus subtypes. Methods for detection and clinical and pathological implications |
| Q114668981 | Assessment of the clinical and cost-effectiveness evidence in the reimbursement decisions of new cancer drugs |
| Q54647675 | Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer. |
| Q55027355 | Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies: exploratory analyses of the RAISE trial and validation in an electronic medical record d |
| Q90861328 | Association of homogeneous inflamed gene signature with a better outcome in patients with metastatic melanoma treated with MAGE-A3 immunotherapeutic |
| Q95324139 | Association of programmed cell death ligand 1 and circulating lymphocytes with risk of venous thromboembolism in patients with glioma |
| Q102210211 | Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results? |
| Q91047162 | Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: a case report and a review of literature |
| Q100761050 | Aurora kinases in ovarian cancer |
| Q91710470 | Awareness of predatory journals and open access among medical oncologists: results of an online survey |
| Q91737294 | Awareness of predatory publishing |
| Q90292001 | B7x-from bench to bedside |
| Q57299887 | BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance |
| Q55080436 | BRCA mutation carrier detection. A model-based cost-effectiveness analysis comparing the traditional family history approach and the testing of all patients with breast cancer. |
| Q54227107 | Back to the 'essence' of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines. |
| Q64114213 | Benefit from anti-EGFRs in and wild-type metastatic transverse colon cancer: a clinical and molecular proof of concept study |
| Q90861340 | Benefit of adjuvant chemotherapy based on lymph node involvement for oesophageal cancer following trimodality therapy |
| Q114877537 | Benefit of pazopanib in advanced gastrointestinal stromal tumours: results from a phase II trial (SSG XXI, PAGIST) |
| Q111434622 | Beta-blockers in early-stage breast cancer: a systematic review and meta-analysis |
| Q55224120 | Between January 2009 and April 2016, 134 novel anticancer therapies were approved: what is the level of knowledge concerning the clinical benefit at the time of approval? |
| Q120496159 | Beyond the lessons learned from the COVID-19 pandemic: opportunities to optimize clinical trial implementation in oncology |
| Q54958979 | Biologics and biosimilars: what, why and how? |
| Q55000770 | Biology of premature ageing in survivors of cancer. |
| Q54974112 | Biosimilars as a strategy to improve sustainability. |
| Q59138150 | Biosimilars in oncology |
| Q55007675 | Biosimilars. |
| Q54135887 | Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers. |
| Q101563759 | Body weight and return to work among survivors of early-stage breast cancer |
| Q90711328 | Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion |
| Q98574865 | Brain microenvironment-driven resistance to immune and targeted therapies in acral melanoma |
| Q102058745 | Bratislava Statement: consensus recommendations for improving pancreatic cancer care |
| Q99207281 | Breast Cancer: global quality care optimizing care delivery with existing financial and personnel resources |
| Q104745973 | Breast cancer in very young women-a multicenter 10-year experience |
| Q100453951 | Breast cancer subtypes: implications for the treatment and survival of patients in Africa-a prospective cohort study from Mozambique |
| Q94597520 | Brief letter of a doctor to his psychologist in the COVID-19 outbreak era |
| Q97519696 | Buparlisib plus carboplatin or lomustine in patients with recurrent glioblastoma: a phase Ib/II, open-label, multicentre, randomised study |
| Q102141013 | CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket? |
| Q91673689 | CDK4/6 inhibition in low burden and extensive metastatic breast cancer: summary of an ESMO Open-Cancer Horizons pro and con discussion |
| Q57107726 | CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion |
| Q54986756 | CECOG educational illustrations: the blood-brain barrier and its relevance for targeted cancer therapies and immuno-oncology. |
| Q101409692 | COVID-19 risk for patients undergoing anticancer treatment at the outpatient clinic of the National Cancer Institute of Milan: the COVINT study |
| Q55362219 | CSCO joins ESMO Open-Cancer Horizons. |
| Q64958984 | CSF-1 and Ang-2 serum levels - prognostic and diagnostic partners in non-small cell lung cancer. |
| Q94547845 | Call for ensuring cancer care continuity during COVID-19 pandemic |
| Q98621903 | Calling for advocacy, education and public policy actions on pain control for patients with cancer in Africa |
| Q97526280 | Can multigene assays widen their clinical usefulness in early breast cancer treatment choice during the current COVID-19 outbreak in Italy? |
| Q28069620 | Can we predict toxicity and efficacy in older patients with cancer? Older patients with colorectal cancer as an example |
| Q28068579 | Cancer and liver cirrhosis: implications on prognosis and management |
| Q54969186 | Cancer and the arts: Johannes Brahms and the problem of pancreatic carcinoma. |
| Q54839129 | Cancer and the arts: La Madonna dei Tumori, Ravenna, Italy. |
| Q58757735 | Cancer and the arts: a Pacifist's Guide to the War on Cancer |
| Q89494920 | Cancer and the arts: how often do doctors only see what they want to see? Or: the case of an 'epidemic of breast cancer among famous artists' |
| Q54974731 | Cancer and the arts: metastasis-as perceived through the ages. |
| Q88863399 | Cancer and the arts: the fight for meaning - Akira Kurosawa's "Ikiru" |
| Q55060960 | Cancer and the arts: why we need works by long-term survivors. |
| Q90765494 | Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists' perspective |
| Q122941516 | Cancer care in transgender and gender-diverse persons: results from two national surveys among providers and health service users by the Italian Association of Medical Oncology |
| Q28072071 | Cancer clinical research in Latin America: current situation and opportunities. Expert opinion from the first ESMO workshop on clinical trials, Lima, 2015 |
| Q95837704 | Cancer datasets and the SARS-CoV-2 pandemic: establishing principles for collaboration |
| Q54896960 | Cancer drugs, survival and ethics: a critical look from the inside. |
| Q54260838 | Cancer genome: highlights of a Nature Medicine perspective. |
| Q54055141 | Cancer immune cycle: a video introduction to the interaction between cancer and the immune system. |
| Q28076763 | Cancer in pregnancy: disentangling treatment modalities |
| Q92684886 | Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough? |
| Q60933076 | Cancer research in the era of immunogenomics |
| Q55209489 | Carboplatin dose based on actual renal function: no excess of acute haematotoxicity in adjuvant treatment in seminoma stage I. |
| Q55438414 | Cardiotoxicity of immune checkpoint inhibitors. |
| Q89807860 | Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials |
| Q92972179 | Care of adolescents and young adults with cancer in Asia: results of an ESMO/SIOPE/SIOP Asia survey |
| Q54975074 | Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO). |
| Q99608128 | Caring for the caregiver: a systematic review characterising the experience of caregivers of older adults with advanced cancers |
| Q54581789 | Case report: impressive response to pembrolizumab in a patient with mismatch-repair deficient metastasized colorectal cancer and bulky disease. |
| Q28069040 | Challenge of cancer in the elderly |
| Q90861333 | Challenge of implementing clinical practice guidelines. Getting ESMO's guidelines even closer to the bedside: introducing the ESMO Practising Oncologists' checklists and knowledge and practice questions |
| Q123308105 | Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey |
| Q64094659 | Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication |
| Q112701354 | Characterizing kinase intergenic-breakpoint rearrangements in a large-scale lung cancer population and real-world clinical outcomes |
| Q54988181 | Checkpoint inhibitors in the treatment of urological malignancies. |
| Q123347576 | Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review |
| Q54962992 | Chemotherapy in cancer patients undergoing haemodialysis: a nationwide study in Japan. |
| Q90050818 | Chemotherapy plus bevacizumab as an optimal first-line therapeutic treatment for patients with right-sided metastatic colon cancer: a meta-analysis of first-line clinical trials |
| Q90573071 | Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis |
| Q90299761 | Choosing wisely in oncology: necessity and obstacles |
| Q54983901 | Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression. |
| Q55385744 | Clinical activity and tolerability of FOLFIRI and cetuximab in elderly patients with metastatic colorectal cancer in the CAPRI-GOIM first-line trial. |
| Q64889458 | Clinical and molecular determinants of extrahepatic disease progression in patients with metastatic colorectal cancer with liver-limited metastases deemed initially unresectable. |
| Q104745969 | Clinical and molecular practice of European thoracic pathology laboratories during the COVID-19 pandemic. The past and the near future |
| Q128179198 | Clinical benefit of anti-PD-(L)1 immunotherapies in advanced cancer in France: a population-based estimate from 2014 to 2021 |
| Q91710464 | Clinical insights on outcomes of corticosteroid administration in immune checkpoint inhibitor-induced pneumonitis by retrospective case series analysis |
| Q55080669 | Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment. |
| Q55294897 | Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme. |
| Q98574868 | Clinical outcomes of patients with breast cancer relapsing after (neo)adjuvant trastuzumab and receiving trastuzumab rechallenge or lapatinib-based therapy: a multicentre retrospective cohort study |
| Q100533131 | Clinical research disruption in the post-COVID-19 era: will the pandemic lead to change? |
| Q90437266 | Clinical scoring system for the prediction of survival of patients with advanced gastric cancer |
| Q102210204 | Clinical significance of ERBB2 exon 16 skipping: analysis of a real-world retrospective observational cohort study |
| Q55033775 | Clinical value of early detection of circulating tumour DNA-BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor. |
| Q54849840 | Clonal evolution and KRAS-MET coamplification during secondary resistance to EGFR-targeted therapy in metastatic colorectal cancer. |
| Q104745961 | Clonal evolution in diffuse large B-cell lymphoma with central nervous system recurrence |
| Q55265741 | Clonal evolution of colorectal cancer in a patient with serially resected metastases and liquid biopsies: a case report and discussion of the literature. |
| Q98732998 | Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects |
| Q91673696 | Community-driven development of a modified progression-free survival ratio for precision oncology |
| Q99233442 | Comparative analysis of antibiotic exposure association with clinical outcomes of chemotherapy versus immunotherapy across three tumour types |
| Q54989492 | Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences? |
| Q114180883 | Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels |
| Q99616291 | Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer |
| Q102141007 | Completion rate and impact on physician-patient relationship of video consultations in medical oncology: a randomised controlled open-label trial |
| Q54116611 | Comprehensive molecular screening by next generation sequencing reveals a distinctive mutational profile of KIT/PDGFRA genes and novel genomic alterations: results from a 20-year cohort of patients with GIST from north-western Greece. |
| Q55186392 | Concerning the article by Louveau et al "Clinical value of early detection of circulating tumour DNA BRAFV600mut in patients with metastatic melanoma treated with a BRAF inhibitor". |
| Q55366227 | Concerns with conclusions in the article by Sherwood et al 'Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice'. |
| Q55022999 | Consensus on management of metastatic colorectal cancer in Central America and the Caribbean: San José, Costa Rica, August 2016. |
| Q55022893 | Contemporary outcomes from the use of regular imaging to detect relapse in high-risk cutaneous melanoma. |
| Q54143053 | Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study. |
| Q91710482 | Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project |
| Q55686663 | Controversies and consensus of neoadjuvant chemotherapy in soft-tissue sarcomas. |
| Q64880678 | Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making? |
| Q55517923 | Controversies in oncology: surgery for small cell lung cancer? It's time to rethink the case. |
| Q54974390 | Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer? |
| Q129716018 | Controversies in upper GI oncology: MSI-H in gastroesophageal adenocarcinoma |
| Q88886302 | Correction |
| Q64107060 | Correction: |
| Q98574862 | Correction: Bone health management in the continuum of prostate cancer disease: a review of the evidence with an expert panel opinion |
| Q90156135 | Correction: European society for medical oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows |
| Q95324183 | Correction: Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli' |
| Q89900672 | Correction: Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice |
| Q103825792 | Correction: Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project) |
| Q98906140 | Correction: Molecular profile of BRCA-mutated biliary tract cancers |
| Q100944711 | Correction: Oncological care organisation during COVID-19 outbreak |
| Q90789915 | Correction: PO-194 Novel potential targets for hakai oncogene during tumour progression |
| Q58698381 | Correction: Preparing for the incoming wave of biosimilars in oncology |
| Q96124418 | Correction: STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort |
| Q92972173 | Correction: Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case |
| Q92771625 | Correction: Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials |
| Q123291497 | Corrigendum to ‘Checkpoint inhibitors, fertility, pregnancy, and sexual life: a systematic review’ |
| Q28072563 | Critically ill patients with cancer: chances and limitations of intensive care medicine-a narrative review |
| Q90437250 | Current challenges in the implementation of precision oncology for the management of metastatic colorectal cancer |
| Q90659935 | Current models, challenges and best practices for work conducted between European academic cooperative groups and industry |
| Q98575133 | Current status and future potential of predictive biomarkers for immune checkpoint inhibitors in gastric cancer |
| Q92972106 | Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab |
| Q55008951 | Descriptive statistical analysis of a real life cohort of 2419 patients with brain metastases of solid cancers. |
| Q94552591 | Desmoid tumours: a perfect example for making progress in treatment management through international collaboration |
| Q54981288 | Detailed statistical assessment of the characteristics of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) threshold rules. |
| Q99616289 | Detection of postoperative plasma circulating tumour DNA and lack of CDX2 expression as markers of recurrence in patients with localised colon cancer |
| Q98648097 | Development of circulating tumour DNA analysis for gastrointestinal cancers |
| Q92241725 | Development of new therapies for metastatic pancreatic cancer: are they better than FOLFIRINOX? |
| Q64087179 | Development of sodium fluoride PET response criteria for solid tumours (NAFCIST) in a clinical trial of radium-223 in osteosarcoma: from RECIST to PERCIST to NAFCIST |
| Q28076646 | Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology |
| Q114190952 | Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries |
| Q55408178 | Differential research impact in cancer practice guidelines' evidence base: lessons from ESMO, NICE and SIGN. |
| Q122416458 | Dignity of science and the use of ChatGPT as a co-author |
| Q54522529 | Discussing and prescribing expensive unfunded anticancer drugs in Australia. |
| Q101563762 | Discussing motherhood when the oncological prognosis is dire: ethical considerations for physicians |
| Q55025094 | Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. |
| Q54912094 | Does clinical trial participation improve outcomes in patients with ovarian cancer? |
| Q59327186 | Dose escalation of axitinib on disease progression as a strategy in the treatment of metastatic renal cell carcinoma |
| Q54947553 | Drug development: successes, problems and pitfalls-the industry perspective. |
| Q92771675 | EHA evaluation of the ESMO-Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies |
| Q28066272 | ESMO - Magnitude of Clinical Benefit Scale V.1.0 questions and answers |
| Q27928062 | ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016 |
| Q58694200 | ESMO 2018 presidential symposium—IMpassion130: atezolizumab+nab-paclitaxel in triple-negative breast cancer |
| Q94561146 | ESMO Clinical Research Observatory (ECRO): improving the efficiency of clinical research through rationalisation of bureaucracy |
| Q55547427 | ESMO Copenhagen 2016: a lung cancer 'grand cru'. |
| Q54943251 | ESMO Leaders Generation Programme: an alumni insight. |
| Q95318554 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer |
| Q96683040 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer |
| Q95321756 | ESMO Management and treatment adapted recommendations in the COVID-19 era: Pancreatic Cancer |
| Q94590733 | ESMO Open special series on new emerging targets in cancer immunotherapy |
| Q55091196 | ESMO Open welcomes the association with the Japanese Society of Medical Oncology (JSMO). |
| Q54836371 | ESMO Open-Cancer Horizons and the future of oncology. |
| Q94669593 | ESMO Open: news in breast cancer 2019 |
| Q54945984 | ESMO Women for Oncology 2016: a very personal tale of my professional life in Asia. |
| Q54866473 | ESMO and WHO: 14 years of working in partnership on cancer control. |
| Q126387421 | ESMO expert consensus statements on the screening and management of financial toxicity in patients with cancer |
| Q28079204 | ESMO gave me a chance to help make a difference: a personal reflection on the occasion of receiving the 2015 ESMO Award |
| Q95837626 | ESMO management and treatment adapted recommendations in the COVID-19 era: colorectal cancer |
| Q97901462 | ESMO management and treatment adapted recommendations in the COVID-19 era: gynaecological malignancies |
| Q90437278 | ESMO presidential symposium wrap up: the ClarIDHy trial |
| Q91047170 | ESMO-Magnitude of Clinical Benefit Scale (MCBS) group |
| Q104745962 | ESMO20 YO for YO: highlights on adjuvant CDK4/6 inhibitors in early hormone receptor-positive/HER2-negative breast cancer |
| Q104745963 | ESMO20 YO for YO: highlights on immune checkpoint blockade for triple-negative breast cancer |
| Q104745967 | ESMO20 YO for YO: highlights on metastatic NSCLC-Keynote 024 update |
| Q104745970 | ESMO20 YO for YO: highlights on metastatic renal cell carcinoma-the CheckMate-9ER trial |
| Q104745964 | ESMO20 YO for YO: highlights on new drugs in advanced breast cancer focusing on sacituzumab govitecan and alpelisib |
| Q104745971 | ESMO20 YO for YO: highlights on oncogene-addicted NSCLC |
| Q104745968 | ESMO20 YO for YO: highlights on upper GI tumours |
| Q64094655 | Early use of steroids affects immune cells and impairs immunotherapy efficacy |
| Q94518825 | Editorial debate: Challenges an oncologist has to face during the SARS-CoV-2 pandemic within a universal healthcare system |
| Q94518828 | Editorial debate: Challenges we oncologists, working within a universal healthcare system, have to face in these hard times |
| Q54839303 | Editorial on an international survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. |
| Q92241720 | Educational needs in gastrointestinal cancer: a consensus position paper from the ESMO Gastrointestinal Cancer Faculty |
| Q55402649 | Educational video: the role of PD-L1 in the local tumour microenvironment. |
| Q98575125 | Effect of trifluridine/tipiracil in patients treated in RECOURSE by prognostic factors at baseline: an exploratory analysis |
| Q55411853 | Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. |
| Q58694204 | Efficacy and safety of ramucirumab-containing chemotherapy in patients with pretreated metastatic gastric neuroendocrine carcinoma |
| Q54878242 | Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. |
| Q113874542 | Efficacy, safety and quality-of-life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: results of the TALLISUR trial |
| Q90291969 | Elevated CRP levels indicate poor progression-free and overall survival on cancer patients treated with PD-1 inhibitors |
| Q55026060 | Emerging challenges of advanced squamous cell lung cancer. |
| Q55308858 | Empirical antimicrobial treatment in haemato-/oncological patients with neutropenic sepsis. |
| Q113874538 | Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience |
| Q98732996 | Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis |
| Q99247187 | Entrectinib approval by EMA reinforces options for ROS1 and tumour agnostic NTRK targeted cancer therapies |
| Q58801444 | Epigenetic biomarkers in cancer |
| Q54963093 | Eribulin for metastatic breast cancer (MBC) treatment: a retrospective, multicenter study based in Campania, south Italy (Eri-001 trial). |
| Q55261645 | Erlotinib intercalating pemetrexed/cisplatin versus erlotinib alone in Chinese patients with brain metastases from lung adenocarcinoma: a prospective, non-randomised, concurrent controlled trial (NCT01578668). |
| Q54438811 | Essentials for clinicians: head and neck tumours and neuro-oncology. |
| Q55346468 | European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. |
| Q102058740 | European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma |
| Q90292016 | European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy |
| Q94552587 | European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis |
| Q90060372 | European Society for Medical Oncology (ESMO) 2018 Congress Twitter analysis: from ethics to results through the understanding of communication and interaction flows |
| Q95324186 | Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome |
| Q101120496 | Evaluation of the contribution of randomised cancer clinical trials evaluating agents without documented single-agent activity |
| Q98733000 | Evaluation of the use and efficacy of (neo)adjuvant chemotherapy in angiosarcoma: a multicentre study |
| Q60049458 | Evaluation of time to failure of strategy as an alternative surrogate endpoint in patients with lung cancer with EGFR mutations |
| Q90291980 | Ex vivo lung cancer spheroids resemble treatment response of a patient with NSCLC to chemotherapy and immunotherapy: case report and translational study |
| Q104457245 | Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports |
| Q91641997 | Expanding the TNM for cancers of the colon and rectum using machine learning: a demonstration |
| Q55135199 | Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size. |
| Q92006283 | Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer |
| Q100533128 | Exploratory analysis of circulating cytokines in patients with metastatic breast cancer treated with eribulin: the TRANSERI-GONO (Gruppo Oncologico del Nord Ovest) study |
| Q92771659 | Exploratory analysis of front-line therapies in REVEL: a randomised phase 3 study of ramucirumab plus docetaxel versus docetaxel for the treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy |
| Q90291956 | Exploratory findings from a prematurely closed international, multicentre, academic trial: RAVELLO, a phase III study of regorafenib versus placebo as maintenance therapy after first-line treatment in RAS wild-type metastatic colorectal cancer |
| Q55286218 | Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma. |
| Q91047168 | Extension of the European Medicines Agency (EMA) approval of trifluridine/tipiracil for gastric cancer |
| Q55058184 | External quality assessment for EGFR mutations in Italy: improvements in performances over the time. |
| Q58757748 | Extra cost of brain metastases (BM) in patients with non-squamous non-small cell lung cancer (NSCLC): a French national hospital database analysis |
| Q55384042 | Extrapolation concept at work with biosimilar: a decade of experience in oncology. |
| Q101120491 | FOLFIRINOX or FOLFOXIRI in locally advanced duodenal adenocarcinoma: are we missing out? |
| Q101225152 | FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: the randomised phase III VISNÚ-1 trial |
| Q102210216 | Factors associated with the aggressiveness of care at the end of life for patients with cancer dying in hospital: a nationwide retrospective cohort study in mainland Portugal |
| Q64062061 | Factors associated with treatment delay in women with primary breast cancer who were referred to reproductive specialists |
| Q92771652 | Familial adenomatosis polyposis-related desmoid tumours treated with low-dose chemotherapy: results from an international, multi-institutional, retrospective analysis |
| Q97881742 | Feasibility of high-throughput sequencing in clinical routine cancer care: lessons from the cancer pilot project of the France Genomic Medicine 2025 plan |
| Q90801758 | Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli' |
| Q91641991 | Female oncologists in the Middle East and North Africa: progress towards gender equality |
| Q113874544 | Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer |
| Q54986606 | Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer. |
| Q103825787 | First results of the EORTC-SPECTA/Arcagen study exploring the genomics of rare cancers in collaboration with the European reference network EURACAN |
| Q101049993 | First-in-human pharmacokinetics of tamoxifen and its metabolites in the milk of a lactating mother: a case study |
| Q104457246 | First-line PARP inhibitors in ovarian cancer: summary of an ESMO Open - Cancer Horizons round-table discussion |
| Q92771667 | First-line and second-line treatment of patients with metastatic pancreatic adenocarcinoma in routine clinical practice across Europe: a retrospective, observational chart review study |
| Q97529671 | Five-year review of corticosteroid duration and complications in the management of immune checkpoint inhibitor-related diarrhoea and colitis in advanced melanoma |
| Q64229197 | Flucelvax Tetra: a surface antigen, inactivated, influenza vaccine prepared in cell cultures |
| Q54238201 | Four distinct immune microenvironment subtypes in gastric adenocarcinoma with special reference to microsatellite instability. |
| Q90291994 | From crizotinib to lorlatinib: continuous improvement in precision treatment of ALK-positive non-small cell lung cancer |
| Q98575122 | Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer |
| Q55362111 | Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy? |
| Q98574053 | Gender and sex disparity in cancer trials |
| Q94472862 | Gender climate in Indian oncology: national survey report |
| Q97417114 | Gender gap: surveying the world for tomorrow |
| Q58694191 | Gender influence on professional satisfaction and gender issue perception among young oncologists. A survey of the Young Oncologists Working Group of the Italian Association of Medical Oncology (AIOM) |
| Q122957679 | Gender influence on work satisfaction and leadership for medical oncologists: a survey of the Spanish Society of Medical Oncology (SEOM) |
| Q122966448 | Gender representation on editorial boards of leading oncology journals |
| Q57071160 | Gender-related challenges facing oncologists: the results of the ESMO Women for Oncology Committee survey |
| Q101224970 | Gender-specific aspects of epidemiology, molecular genetics and outcome: lung cancer |
| Q101049965 | Gender-specific aspects related to type of fertility preservation strategies and access to fertility care |
| Q91047158 | Genetic mapping of pancreatic cancer by targeted next-generation sequencing in a cohort of patients managed with nab-paclitaxel-based chemotherapy or agents targeting the EGFR axis: a retrospective analysis of the Hellenic Cooperative Oncology Group |
| Q64111570 | Genomic heterogeneity and efficacy of PI3K pathway inhibitors in patients with gynaecological cancer |
| Q90050897 | Genomic-guided precision therapy for soft tissue sarcoma |
| Q55100041 | Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases. |
| Q104745952 | Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort |
| Q55035816 | Global cancer control: responding to the growing burden, rising costs and inequalities in access. |
| Q128788352 | Guidelines for the diagnosis and treatment of cutaneous squamous cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology |
| Q92241712 | HER2-targeted therapy should be shifted towards an earlier line for patients with anti-EGFR-therapy naïve, HER2-amplified metastatic colorectal cancer |
| Q100958295 | Haematopoietic stem cell transplantation in adult soft-tissue sarcoma: an analysis from the European Society for Blood and Marrow Transplantation |
| Q54867398 | Hallmarks of glioblastoma: a systematic review. |
| Q55152175 | Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study. |
| Q102378013 | Healthcare use and costs in early breast cancer: a patient-level data analysis according to stage and breast cancer subtype |
| Q89494887 | Heterogeneity of colon cancer: from bench to bedside |
| Q90861314 | High incidence of cetuximab-related infusion reactions in head and neck patients |
| Q28075787 | Highlights for ESMO 40: celebration review for lifetime achievement awards |
| Q54978882 | Highlights from the San Antonio Breast Cancer Symposium 2015. |
| Q55176173 | Highlights in breast cancer from ASCO 2016. |
| Q89700296 | Highlights in lung cancer in 2019 |
| Q98234990 | Hormonal control of cancer: an outdated topic? |
| Q92684950 | How I treat ALK-positive non-small cell lung cancer |
| Q98158289 | How I treat MALT lymphoma: 'a subjective interpretation of the gospel according to Isaacson….' |
| Q64944737 | How I treat MSI cancers with advanced disease. |
| Q91710508 | How I treat NTRK gene fusion-positive cancers |
| Q98664561 | How I treat adverse effects of CAR-T cell therapy |
| Q98944489 | How I treat anal squamous cell carcinoma |
| Q90292021 | How I treat anaplastic glioma without 1p/19q codeletion |
| Q64890286 | How I treat cancer special issue. |
| Q92771647 | How I treat cancer-associated thrombosis |
| Q92684962 | How I treat cancer: treatment of rheumatological side effects of immunotherapy |
| Q64900660 | How I treat cancers of unknown primary. |
| Q92241733 | How I treat gastric adenocarcinoma |
| Q90198734 | How I treat malignant pleural mesothelioma |
| Q92684942 | How I treat metastatic melanoma |
| Q92972224 | How I treat metastatic triple-negative breast cancer |
| Q98575136 | How I treat neuroendocrine tumours |
| Q98575147 | How I treat pancreatic cancer |
| Q90292027 | How I treat squamous ENT cancer |
| Q55316580 | How many diseases is triple negative breast cancer: the protagonism of the immune microenvironment. |
| Q54965602 | How shall we treat early triple-negative breast cancer (TNBC): from the current standard to upcoming immuno-molecular strategies. |
| Q104745960 | How we treat endocrine complications of immune checkpoint inhibitors |
| Q91812608 | How we treat glioblastoma |
| Q98575144 | How we treat metastatic colorectal cancer |
| Q92684971 | How we treat neurological toxicity from immune checkpoint inhibitors |
| Q94684157 | How we treat patients with brain tumour during the COVID-19 pandemic |
| Q64955303 | How we treat patients with leptomeningeal metastases. |
| Q94684154 | How we treat patients with lung cancer during the SARS-CoV-2 pandemic |
| Q91554260 | How we treat patients with lung cancer during the SARS-CoV-2 pandemic: primum non nocere |
| Q64939865 | Hyperprogressive disease during nivolumab or irinotecan treatment in patients with advanced gastric cancer. |
| Q55080476 | I-SPY 2: optimising cancer drug development in the 21st century. |
| Q122969789 | Identifying and preventing burnout in young oncologists, an overwhelming challenge in the COVID-19 era: a study of the Spanish Society of Medical Oncology (SEOM) |
| Q28079771 | Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel? |
| Q54966701 | Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management. |
| Q91812593 | Immune checkpoint inhibitor treatment in patients with oncogene- addicted non-small cell lung cancer (NSCLC): summary of a multidisciplinary round-table discussion |
| Q55082051 | Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. |
| Q57822393 | Immune checkpoint inhibitors for every patient with non-small cell lung cancer? Update on immunotherapy in patients with lung cancer |
| Q88646657 | Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found… |
| Q88762624 | Immune-related response criteria: light and shadows |
| Q90711347 | Immunohistochemical validation study of 15-gene biomarker panel predictive of benefit from adjuvant chemotherapy in resected non-small-cell lung cancer: analysis of JBR.10 |
| Q104745966 | Immunological inflammatory biomarkers as prognostic predictors for advanced hepatocellular carcinoma |
| Q60960900 | Immunotherapy for hepatocellular carcinoma: current status and future perspectives |
| Q55308068 | Immunotherapy in lung cancer. |
| Q100958296 | Impact of COVID-19 on anxiety levels among patients with cancer actively treated with systemic therapy |
| Q103825791 | Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians |
| Q97566161 | Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma |
| Q57170878 | Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study |
| Q123134240 | Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study |
| Q55208892 | Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. |
| Q102053467 | Impact of clinical versus radiographic progression on clinical outcomes in metastatic castration-resistant prostate cancer |
| Q54628350 | Impact of intervention aimed at improving the integration of oncology units and local palliative care services: results of the multicentre prospective sequential MIRTO study. |
| Q89700294 | Impact of prior cancer history on the overall survival of younger patients with lung cancer |
| Q99727027 | Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis |
| Q96639578 | Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain |
| Q94552581 | Impact of tumour growth rate during preceding treatment on tumour response to regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer |
| Q91047163 | Implementation of lung cancer screening in Europe: challenges and potential solutions: summary of a multidisciplinary roundtable discussion |
| Q64229216 | Implementing TMB measurement in clinical practice: considerations on assay requirements |
| Q102388054 | Implementing clinical practice guidelines: time to assess it |
| Q55449354 | Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate. |
| Q64994221 | Importance of genetic screens in precision oncology. |
| Q97903480 | Improved efficacy of taxanes and ramucirumab combination chemotherapy after exposure to anti-PD-1 therapy in advanced gastric cancer |
| Q55035714 | In the literature: April 2017. |
| Q55021644 | In the literature: April 2018. |
| Q92972168 | In the literature: April 2019 |
| Q92128346 | In the literature: April 2020 |
| Q92684935 | In the literature: August 2018 |
| Q58780159 | In the literature: August 2018 |
| Q98574907 | In the literature: August 2020 |
| Q125128035 | In the literature: August 2021 |
| Q60049457 | In the literature: December 2018 |
| Q92771636 | In the literature: December 2019 |
| Q104745958 | In the literature: December 2020 |
| Q55083430 | In the literature: February 2017. |
| Q55028337 | In the literature: February 2018. |
| Q64280651 | In the literature: February 2019 |
| Q89807865 | In the literature: February 2020 |
| Q55242537 | In the literature: June 2018. |
| Q91812600 | In the literature: June 2019 |
| Q97529733 | In the literature: June 2020 |
| Q54877466 | In the literature: March 2016. |
| Q55116636 | In the literature: May 2016. |
| Q54023284 | In the literature: October 2016. |
| Q59138833 | In the literature: October 2018 |
| Q91673718 | In the literature: October 2019 |
| Q100512002 | In the literature: October 2020 |
| Q55254683 | Incidence of cetuximab-related infusion reaction in head and neck cancer patients: may we predict it? |
| Q99616292 | Increasing completion of asparaginase treatment in childhood acute lymphoblastic leukaemia (ALL): summary of an expert panel discussion |
| Q94472860 | Indications regarding the management of interventional clinical trials with drugs during the current COVID-19 emergency in Italy |
| Q64905201 | Indicators of integration at ESMO Designated Centres of Integrated Oncology and Palliative Care. |
| Q54974210 | Indispensable benefit of independent investigator-driven research in a changing clinical trial landscape. |
| Q53990140 | Indolent peritoneal mesothelioma: PI3K-mTOR inhibitors as a novel therapeutic strategy. |
| Q99349386 | Induction of natural killer antibody-dependent cell cytotoxicity and of clinical activity of cetuximab plus avelumab in non-small cell lung cancer |
| Q96300938 | Infection rate and clinical management of cancer patients during the COVID-19 pandemic: experience from a tertiary care hospital in northern Italy |
| Q91815526 | Infection risk with PI3K-AKT-mTOR pathway inhibitors and immune checkpoint inhibitors in patients with advanced solid tumours in phase I clinical trials |
| Q100944714 | Influenza in hospitalised patients with malignancy: a propensity score matching analysis |
| Q55068559 | Initial experience with the bispecific anti-CEA anti-CD3 antibody and its expected impact on future treatment for patients with colorectal cancer. |
| Q91368844 | Innovative oncology products: time to revisit the strategy development? |
| Q28066709 | Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls |
| Q112641619 | Integrative molecular analysis of combined small-cell lung carcinomas identifies major subtypes with different therapeutic opportunities |
| Q54703477 | Inter-institutional heterogeneity in outcomes of chemotherapy for metastatic gastric cancer: correlative study in the JCOG9912 phase III trial. |
| Q92684916 | Interim analysis of a real-world precision medicine platform for molecular profiling of metastatic or advanced cancers: MONDTI |
| Q54917990 | International survey of androgen deprivation therapy (ADT) for non-metastatic prostate cancer in 19 countries. |
| Q64280661 | Interprofessional spiritual care in oncology: a literature review |
| Q28067650 | Interventions to improve care coordination between primary healthcare and oncology care providers: a systematic review |
| Q92241738 | Introducing a new ESMO Open article series: how I treat side effects of immunotherapy |
| Q58694056 | Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC |
| Q55070614 | Is CBOP/BEP an alternative to BEP for patients with poor prognosis metastatic germ cell tumours? |
| Q58790699 | Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer? |
| Q28069764 | KRAS-driven lung adenocarcinoma: combined DDR1/Notch inhibition as an effective therapy |
| Q55083559 | Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice. |
| Q64056304 | Knowledge and use of biosimilars in oncology: a survey by the European Society for Medical Oncology |
| Q104745972 | Knowledge, attitudes and practices related to the COVID-19 outbreak among Romanian adults with cancer: a cross-sectional national survey |
| Q95934747 | LKB1 mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial |
| Q54918960 | Lactobacillus brevis CD2 lozenges prevent oral mucositis in patients undergoing high dose chemotherapy followed by haematopoietic stem cell transplantation. |
| Q101241760 | Late decisions about treatment limitation in patients with cancer: empirical analysis of end-of-life practices in a haematology and oncology unit at a German university hospital |
| Q126003464 | Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology—shared perspectives from international consortia |
| Q90437273 | Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer |
| Q99204235 | Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1. |
| Q54856582 | Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis. |
| Q90291965 | Liquid biopsy assessment of synchronous malignancies: a case report and review of the literature |
| Q55340002 | Liquid biopsy for HER2-positive breast cancer brain metastasis: the role of the cerebrospinal fluid. |
| Q113874540 | Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study |
| Q104745955 | Longitudinal characterisation of haematological and biochemical parameters in cancer patients prior to and during COVID-19 reveals features associated with outcome |
| Q57214474 | Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity |
| Q102074643 | Lower risk of severe checkpoint inhibitor toxicity in more advanced disease |
| Q102210208 | Lung cancer symptoms at diagnosis: results of a nationwide registry study |
| Q118176618 | Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study |
| Q102388052 | Machine learning: an approach to preoperatively predict PD-1/PD-L1 expression and outcome in intrahepatic cholangiocarcinoma using MRI biomarkers |
| Q58801445 | Macrophage repolarisation therapy in colorectal cancer |
| Q113874536 | Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis |
| Q54775458 | Male breast cancer: finding the way in this uncommon path. |
| Q104281204 | Management of breathlessness in patients with cancer: ESMO Clinical Practice Guidelines† |
| Q55032398 | Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). |
| Q102151751 | Management of orphan symptoms: ESMO Clinical Practice Guidelines for diagnosis and treatment† |
| Q103825784 | Management of patients with early-stage colon cancer: guidelines of the Italian Medical Oncology Association |
| Q55019941 | Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) and the Società Italiana di Nefrologia (SIN). |
| Q54979977 | Management of recurrent or metastatic thyroid cancer. |
| Q60054414 | Management of young women with early breast cancer |
| Q100512000 | Managing toxicities with asparaginase-based therapies in adult ALL: summary of an ESMO Open-Cancer Horizons roundtable discussion |
| Q64933332 | Maximising clinical benefit with adequate patient management beyond the second line in mCRC. |
| Q55060215 | Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer. |
| Q28077415 | Mechanisms of resistance to EGFR-targeted drugs: lung cancer |
| Q102378014 | Mentoring as an opportunity to improve research and cancer care in Latin America (AAZPIRE project) |
| Q54967387 | Metal drugs become targeted. |
| Q96124442 | Metastatic breast cancer and pseudocirrhosis: an unknown clinical entity |
| Q55111318 | Methodological issues in the choice among different drugs approved for the same therapeutic indication: a position paper by the Italian Association of Medical Oncology (AIOM). |
| Q101120497 | MiR-100 is a predictor of endocrine responsiveness and prognosis in patients with operable luminal breast cancer |
| Q64094662 | Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors |
| Q102335571 | Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma |
| Q91368839 | Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review |
| Q28076360 | Molecular pathology of cancer: how to communicate with disease |
| Q96639277 | Molecular profile of BRCA-mutated biliary tract cancers |
| Q104745974 | Molecular profiling of Asian patients with advanced melanoma receiving check-point inhibitor treatment |
| Q99571852 | Molecular target: pan-AKT in gastric cancer |
| Q92972096 | Moving cancer care closer to home: a single-centre experience of home chemotherapy administration for patients with myelodysplastic syndrome |
| Q54620120 | Multicentre phase II study of nivolumab in Japanese patients with advanced or recurrent non-squamous non-small cell lung cancer. |
| Q57652296 | Multidisciplinary molecular tumour board: a tool to improve clinical practice and selection accrual for clinical trials in patients with cancer |
| Q114180880 | Multimodal survival prediction in advanced pancreatic cancer using machine learning |
| Q54942556 | Multiple primary tumours: challenges and approaches, a review. |
| Q98574901 | Mycobacterial infections due to PD-1 and PD-L1 checkpoint inhibitors |
| Q28066821 | NTRK gene fusions as novel targets of cancer therapy across multiple tumour types |
| Q55077233 | NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer. |
| Q102058743 | Natural history and prognostic factors for localised small bowel adenocarcinoma |
| Q90167445 | Neoadjuvant radiotherapy in the approach of locally advanced breast cancer |
| Q64914318 | Neoadjuvant treatment for intermediate/high-risk HER2-positive and triple-negative breast cancers: no longer an 'option' but an ethical obligation. |
| Q102335568 | Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre |
| Q55265980 | Neoadjuvant treatment: the future of patients with breast cancer. |
| Q55068724 | Neutrophil to lymphocyte ratio (NLR) for prediction of distant metastasis-free survival (DMFS) in early breast cancer: a propensity score-matched analysis. |
| Q53981393 | Neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio before chemotherapy as potential prognostic factors in patients with newly diagnosed epithelial ovarian cancer. |
| Q99550699 | New biomarkers for checkpoint inhibitor therapy |
| Q55022021 | New data: new options for front-line therapy in NSCLC? |
| Q91642011 | New emerging targets in cancer immunotherapy beyond CTLA-4, PD-1 and PD-L1: Introducing an "ESMO Open - Cancer Horizons" Series |
| Q96950741 | New emerging targets in cancer immunotherapy: CD137/4-1BB costimulatory axis |
| Q90167531 | New emerging targets in cancer immunotherapy: CD27 (TNFRSF7) |
| Q91642022 | New emerging targets in cancer immunotherapy: the role of Cluster of Differentiation 40 (CD40/TNFR5) |
| Q98575117 | New emerging targets in cancer immunotherapy: the role of GITR |
| Q64994684 | New emerging targets in cancer immunotherapy: the role of LAG3. |
| Q91642003 | New emerging targets in cancer immunotherapy: the role of TIM3 |
| Q96589493 | New emerging targets in cancer immunotherapy: the role of VISTA |
| Q91737349 | New emerging targets in cancer immunotherapy: the role of neoantigens |
| Q54185643 | New horizon in breast cancer therapy: highlights from the European Society for Medical Oncology. |
| Q54476966 | New molecular and immunotherapeutic approaches in biliary cancer. |
| Q94552595 | New pathways in immune stimulation: targeting OX40 |
| Q55607045 | New therapeutic targets in the inflammatory microenvironment. |
| Q54990172 | New treatment options for metastatic renal cell carcinoma. |
| Q89700291 | News on the horizon in glioblastoma therapy |
| Q54963459 | Nivolumab for NSCLC in Japanese patients: similar benefits, but beware of pneumonitis. |
| Q103025953 | Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial |
| Q97635556 | Nivolumab treatment of elderly Japanese patients with non-small cell lung cancer: subanalysis of a real-world retrospective observational study (CA209-9CR) |
| Q55209741 | Nivolumab-induced hypothyroidism and selective pituitary insufficiency in a patient with lung adenocarcinoma: a case report and review of the literature. |
| Q54963997 | Novel active agents in patients with advanced NSCLC without driver mutations who have progressed after first-line chemotherapy. |
| Q54863313 | Novel prognostic prediction models for patients with stage IV colorectal cancer after concurrent curative resection. |
| Q55305291 | Nutrition in patients with cancer: a new area for medical oncologists? A practising oncologist's interdisciplinary position paper. |
| Q89807850 | Olanzapine combined with 5-hydroxytryptamine type 3 receptor antagonist (5-HT3 RA) plus dexamethasone for prevention and treatment of chemotherapy-induced nausea and vomiting in high and moderate emetogenic chemotherapy: a systematic review and meta |
| Q112578636 | Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study) |
| Q92006270 | Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning? |
| Q98732997 | Oncological care organisation during COVID-19 outbreak |
| Q55237909 | One year of ESMO Open: Cancer Horizons-where are we going from here? |
| Q55342871 | Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. |
| Q99593447 | Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era |
| Q55438459 | Oral rehydration solution (OS-1) as a substitute of intravenous hydration after cisplatin administration in patients with lung cancer: a prospective multicenter trial. |
| Q103025958 | Outcomes of patients with metastatic gastrointestinal stromal tumors (GIST) treated with multi-kinase inhibitors other than imatinib as first-line treatment |
| Q101563766 | PD-1 protein and gene expression as prognostic factors in early breast cancer |
| Q90861326 | PHOTOSTENT-02: porfimer sodium photodynamic therapy plus stenting versus stenting alone in patients with locally advanced or metastatic biliary tract cancer |
| Q98574873 | PIK3CA mutation inhibition in hormone receptor-positive breast cancer: time has come |
| Q129589496 | PO-001 Environmental toxins can transform mammary cells and induce chemo-resistance in breast cancer via multiple mechanisms |
| Q129589399 | PO-001 Therapeutic inhibition of trefoil factor 3(TFF3) decrease oncogenic behaviour in non-small cell lung cancer (NSCLC) |
| Q129588557 | PO-002 Angiotensin II-induced hypertension increases the mutation frequency in the rat kidney |
| Q129587260 | PO-002 Single siRNA mediated post transcriptional and transcriptional gene silencing of HPV18 oncogenes |
| Q129586651 | PO-003 Metformin restores nickel-reduced glutathione S-transferase Mu2 expression by promoter methylated alteration |
| Q129587885 | PO-004 Antibodies targeting the heparin-binding domain of fibroblast growth factor receptor 1 for cancer therapy |
| Q129586904 | PO-004 The clinical relevance and functional role of ACADM in hepatocellular carcinoma |
| Q129586799 | PO-005 Prevention strategies for intestinal cancer development in lynch syndrome |
| Q129586702 | PO-006 Generation of recombinant antibody variable fragments in baculovirus expression system targeted against epidermal growth factor receptor mutant expressing glioblastoma |
| Q129588206 | PO-006 The MAPK/c-Myc axis in CRC: new pathogenic mechanisms and therapeutic approaches |
| Q129587190 | PO-007 Investigating the hyperactivation of ERK5 signalling in skin cancer |
| Q129587875 | PO-008 Accelerated DNA methylation in gastric mucosa adjacent to cancer after HELICOBACTER PYLORI eradication |
| Q129587161 | PO-008 Anti-tumour properties of novel multikinase inhibitors in sarcomas: synergistic combination with doxorubicin |
| Q129586693 | PO-009 A novel integrin alpha 5 binding peptide potentiates effects of chemotherapy in pancreatic cancer |
| Q129585880 | PO-009 Investigating the putative cleavage site of C-terminally truncated MRE11 using mass spectrometry and its function on DNA damage repair |
| Q129588930 | PO-010 Dual chemotherapy and photodynamic therapy: a synergistic strategy to improve cancer treatment |
| Q129589470 | PO-010 PRMT1 methylates and regulates the deubiquitinating enzyme USP11 modulating the DNA damage response in breast cancer cells |
| Q129587431 | PO-011 Dihydroartemisinin inhibits TCTP-dependent metastasis in gallbladder cancer |
| Q129588047 | PO-011 Impact of compartment-specific changes in NAD biosynthesis on diethylnitrosamine-induced liver cancer |
| Q129588747 | PO-012 Ferulic acid increases ABT-888 sensitivity in breast cancer cells |
| Q129587354 | PO-012 Pre-clinical insight into how platelet count affects the activity of HDACi resminostat in combination with the multi-kinase inhibitor sorafenib in HCC |
| Q129586013 | PO-013 A novel peptidomimetic targeting NRP1 increases radiosensitivity of medulloblastoma stem cells |
| Q129588308 | PO-013 BRCA1 and BRCA2 next generation sequencing in high-grade serous ovarian cancer |
| Q129587253 | PO-014 Dianhydrogalactitol (vaL-083) reduces glioblastoma tumour progression in vivo, upon bevacizumab-induced hypoxia |
| Q129586154 | PO-014 Targeting PARP1 in XRCC1 deficient sporadic invasive breast cancer or pre-invasive ductal carcinoma in situ for synthetic lethality and chemoprevention |
| Q129586579 | PO-015 DNA damage response reporters in breast cancer |
| Q129589369 | PO-015 Potentiating anti-neoplastic effect of cisplatin by a protein arginine methyltransferase 5 selective inhibitor in lung adenocarcinoma cells |
| Q129586040 | PO-016 Inhibition of cell proliferation by anti-epidermal growth factor receptor (EGFR) aptamer conjugated chitosan/siRNA nanoparticles |
| Q129588547 | PO-016 The role of autophagy-related protein 9B in liver carcinogenesis |
| Q129588507 | PO-017 Androgen deprivation and oxidative phosporylation inhibition pose synergistic antitumor effects in subsets of prostate tumours in vitro |
| Q129586555 | PO-017 Is RECQL4 a novel player in glioblastoma pathogenesis? |
| Q129586704 | PO-018 Acquired DNA damage in adolescent obesity – a promoter and predictor of cancer? |
| Q129587383 | PO-018 Immunogenic potential of cold atmospheric plasma for the treatment of pancreatic cancer |
| Q129588150 | PO-019 PTPN11 is a therapeutic target in KRAS mutant lung cancer |
| Q129587310 | PO-019 Phosphoproteomics to characterise DNA damage response in mouse mammary tumours of different PARP inhibitor susceptibility |
| Q129587999 | PO-020 Discrepancy in efficacy of disulfiram between NUP98-PHF23 fusion acute myelogenous leukaemia cell line and in vivo mouse model: sharing normal hematopoietic stem cells niche |
| Q129588497 | PO-020 Functional characterisation of variant of unknown significate in familial breast cancer |
| Q129588640 | PO-021 Inhibition of MK2 stabilises wild-type P53 and improves temozolomide efficacy in glioblastoma |
| Q129586711 | PO-022 Benzamide class of HDACi differentially enhance sodium iodide symporter expression in breast cancer |
| Q129589273 | PO-022 FISH probes for the detection of high-risk HPV nucleic acid in infected host cells |
| Q129585837 | PO-023 A multi-step framework to analyse high-throughput drug combination screens |
| Q129589108 | PO-024 Perioperative blockade of stress-inflammatory responses improves biomarkers of metastasis in excised tumours and blood samples: phase ii clinical trials in colorectal and breast cancer patients |
| Q129589367 | PO-024 SETD1A regulates cell proliferation by modulating miR205 in triple negative breast cancers (TNBCS) |
| Q129587565 | PO-025 Antiproliferative effects of rosemary (rosmarinus officinalis, L.) extract in colon cancer cells lines |
| Q129589110 | PO-025 Effects of entinostat on cell viability and cell cycle in oral cancer cell lines |
| Q129588823 | PO-026 72 Rosemary (rosmarinus officinalis, L.) extract inhibits cell proliferation and migration in colon cancer cells lines |
| Q129587146 | PO-026 Metformin inhibits the NGF-induced increase c-MYC and VEGF levels in ovarian cancer cells |
| Q129588800 | PO-027 Potential use of BH3 mimetics in the treatment of head and neck cancer |
| Q129586019 | PO-028 Effective targeting of NAD+biosynthesis in patient-derived xenograft models of high-risk paediatric acute lymphoblastic leukaemia |
| Q129589410 | PO-028 Effectiveness and molecular basis of CDK4/6 inhibition in combination with taxanes in pancreatic cancer |
| Q129587951 | PO-029 Angiotensin-(1–7) promotes migration of renal cell carcinomacells with no effect on cell proliferation |
| Q129587671 | PO-029 Supercritical carbon dioxide extract of mucuna pruriens inhibits brain cancer tumour growth in rats |
| Q129586870 | PO-030 Cold atmospheric plasma treatment in breast cancer |
| Q129585795 | PO-030 Functional analysis of mastl mutations in cancer |
| Q129587434 | PO-031 NAA induces antitumoral effects in BXPC3 pancreatic cancer cell line |
| Q129585937 | PO-031 Sensitising P53 mutant HNSCC to oncolytic reovirus (RT3D) by targeting the unfolded protein response |
| Q129586248 | PO-032 Displacement of hexokinase 2 from mitochondria induces mitochondrial Ca2 +overload and caspase-independent cell death in cancer cells |
| Q129586550 | PO-032 The knock-down of ferritin heavy subunit induces xenobiotic-resistance in K562 cells through the activation of NF-kB pathway |
| Q129589253 | PO-033 Anticancer activity of natural high mobility group BOX1 inhibitors in colorectal cancer cells |
| Q129586246 | PO-033 Identification and functional evaluation of monoclonal antibodies specifically targeting human carbonic anhydrase IX |
| Q129588552 | PO-034 Inhibition of lung carcinoma growth and pulmonary metastasis with DIMATE as single agent and in combination with cisplatin |
| Q129588692 | PO-035 LKB1 deficiency renders non-small-cell lung cancer cells sensitive to ERK inhibitor |
| Q129587317 | PO-036 Traditional chinese medicine Ze-Qi-TANG formula induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in lung cancer |
| Q129589376 | PO-037 Role of MARCH8 in esophageal squamous cell carcinoma |
| Q129587157 | PO-037 Targeting mutant p53 with COTI-2: a new approach for the treatment of patients with triple-negative breast cancer? |
| Q129587151 | PO-038 PKC isoforms distinctively modulate telomerase expression and AFP secretion in hepatocellular carcinoma |
| Q129586632 | PO-039 Examination of the anti-tumour and neuropathic side effect responses of first generation and second generation proteasome inhibitors |
| Q129585887 | PO-039 Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells |
| Q129587209 | PO-040 Characterisation of CDK12 knocked out ovarian cancer cell lines |
| Q129588100 | PO-040 Development of a tunable form of interferon alpha for in vivo cancer gene therapy |
| Q129586563 | PO-041 Cold atmospheric plasma: a potentially selective and non-inflammatory anti-cancer therapy |
| Q129587924 | PO-041 TNF pathway in metastatic colorectal cancer according to RAS status and implication of potassium channels |
| Q129587482 | PO-042 Targeting hypoxic pancreatic cancer cells with glucose conjugated lactate dehydrogenase inhibitor NHI-Glc-2 |
| Q129588707 | PO-043 Development of two novel monoclonal antibodies against overexpressed antigens on pancreatic cancer cells for use in diagnosis and therapy |
| Q129586233 | PO-043 Targeting the thiol oxidoreductases ERp57 and PDI hits cancer cells on multiple fronts: proliferation, radioresistance and ER stress response (UPR) |
| Q129589109 | PO-044 Development of flow cytometric assays for CAR T cell manufacturing and patient immunomonitoring |
| Q129589457 | PO-044 Possible involvement of G2/M block defects in cell sensitivity towards ATR inhibitors |
| Q129588192 | PO-045 Evaluating liquid biopsies for methylomic profiling of prostate cancer |
| Q111491249 | PO-045 Marine invertebrate extracts inhibit proliferation, migration and invasion in colon cancer cell models |
| Q129586815 | PO-046 Dual inhibition of JAK and Src: a novel and promising therapeutic combination for pancreatic cancer |
| Q129586037 | PO-046 The antiproliferative activity and cell death effects of four marine invertebrate extracts in colon cancer cells |
| Q129587829 | PO-047 Etarget: a digital science solution to integrate clinical and genomic data for the manchester molecular tumour board (MTB) |
| Q129587351 | PO-047 SOX6 is a direct EWSR1-FLI1 target gene contributing to tumour growth of ewing sarcoma |
| Q129586153 | PO-048 Therapeutic relevance of the cell cycle protein BORA in cancer |
| Q129586168 | PO-048 Therapy response testing using a 3d perfused microfluidic platform |
| Q129587188 | PO-049 EGFR blockade induces a paneth cell-like phenotype with rewired signalling dependencies in CRC tumoursat maximal response |
| Q129588616 | PO-049 Quantitative proteomics unveils key mitotic regulators involved in the transition to androgen independent prostate cancer |
| Q129587289 | PO-050 A molecularly annotated platform of pdx-derived cell lines mirrors the genomic landscape of colorectal cancer |
| Q129585902 | PO-050 Long noncoding RNA, ANRIL positively regulates cell proliferation in a P15/P16-dependent and -independent manners |
| Q129588045 | PO-051 Familial risks and mortality in second primary cancers of ovarian cancer patients |
| Q129585743 | PO-051 GNL1 regulates cell proliferation by associating with RPS20 |
| Q129589219 | PO-052 Selenium status and survival from colorectal cancer in the european prospective investigation of cancer and nutrition |
| Q129589374 | PO-052 Significance of miR-100–5 P/99A-5P and MIR-125B-5P under-expression in malignant germ cell tumours |
| Q129586739 | PO-053 The phospholipase DDHD1 as a new target in colorectal cancer therapy |
| Q129585723 | PO-054 Common genetic variants at the breast cancer risk region 2Q35 map to putative IGFbp5 enhancers |
| Q129588545 | PO-054 Traditional chinese medicine Ze-Qi-tang formula induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in lung cancer |
| Q129587969 | PO-055 STAT6 SIRNA reduces proliferation of and induces apoptosis in the human colon adenocarcinoma cell line HT-29 |
| Q129589299 | PO-056 The epigenetic drugs zebularine and trichostatin a enhanced the TRAIL-induced apoptosis in the aggressive triple negative breast cancer |
| Q129588828 | PO-056 The impact of WNT1-inducible signalling pathway protein 1 polymorphism on hepatocellular carcinoma susceptibility |
| Q129589214 | PO-057 Genetic interaction and pathway based discovery of key regulators in multiple myeloma |
| Q129587258 | PO-057 Genistein, a major isoflavone component, suppresses Src-induced proliferative activity by arresting cell cycle at G2/M through increasing the P53 and P21 levels |
| Q129586225 | PO-058 Unravelling the protective role of androgens/androgen receptorin breast cancer: when BAD goes good |
| Q129587311 | PO-059 Cancer-predisposing variants in alternatively spliced TP53 exons |
| Q129588009 | PO-060 Association between RS10993994 polymorphism in MSMB gene with early-onset prostate cancer in mexican men |
| Q129587309 | PO-060 ErbB2/Her2-dependent downregulation of a transcription factor IRF6 in breast cancer cells is required for their three-dimensional growth |
| Q129587303 | PO-061 BCL-2 family of proteins, BCL-XL and MCL-1, regulate apoptosis and cancer cell survival by different mechanisms |
| Q129588068 | PO-061 Exploring heritable predisposition to paediatric rhabdomyosarcomas |
| Q129586606 | PO-062 BAX and BAK interaction with the mitochondrial permeability transition pore (MPTP) is required for taxol-mediated apoptosis |
| Q129585860 | PO-062 Circulating tumour cells in patients with non-small cell lung cancer exhibit notable heterogeneity |
| Q129586638 | PO-063 Pre-diagnostic unconjugated bilirubin levels and colorectal cancer risk in the european prospective investigation into cancer and nutrition (EPIC) |
| Q129585930 | PO-063 Triterpenoids isolated from natural product regulates TNF(tumour necrosis factor)-mediated RIP(receptor-interacting serine/threonine-protein kinase)1-dependent apoptosis |
| Q129588615 | PO-064 Early birth order and increased risk of lymphoid cancers and allergies in lymphoid cancer families |
| Q129588523 | PO-064 Tubulin-binding anti-cancer polysulfides induce cell death via mitotic arrest and autophagic interference in colon cancer |
| Q129587940 | PO-065 Assessment of prognostic models for stage II/III colon cancer: a hospital-based prospective cohort study |
| Q129588163 | PO-066 Knockdown of cadherin 17 inactivates WNT signalling pathway and induces apoptosis in colorectal cancer cells |
| Q129589239 | PO-066 Risk of malignant neoplasms of blood and lymphatic system of liquidators of the chernobyl accident in the republic of belarus |
| Q129588465 | PO-067 Autophagy modulates response to cisplatin in thyroid cancer cells |
| Q129589380 | PO-067 Thyroid cancer incidence in belarusian residents exposed to chernobyl fallout |
| Q129587435 | PO-068 Atlas of causal risk factors for epithelial ovarian cancer risk: a mendelian randomization analysis in up to 66 450 women |
| Q129586576 | PO-068 Determining how distinct microenvironments alter BCL-2 family dependence in T-cell acute lymphoblastic leukaemia |
| Q129589223 | PO-069 Clinical and histological risk factors for subsequent in situ lesions after a primary diagnosis of ductal carcinoma in situ |
| Q129588128 | PO-070 Evaluation the cytotoxic effect of carmofur on MCF-7 human breast cancer cell line |
| Q129589173 | PO-070 Identification of risk factors for subsequent invasive breast cancer after primary DCIS by transcriptomic profiling |
| Q129585736 | PO-071 Risk factors associated with mortality from kidney diseases in patients diagnosed with multiple myeloma: a population-based analysis |
| Q129587929 | PO-071 Silencing of circRNA004582 sensitises gastric cancer cells to APATINIB via modulating autophagy by targeting miR-3657 and ATG7 |
| Q129589054 | PO-072 Adjusting for systematic technical biases in risk assessment of gene signatures in genomic cohorts |
| Q129587155 | PO-073 Dual targeting of proliferative pathways in BRAF-mutant melanoma cells by PYRIDINYL IMIDAZOLE compounds |
| Q129585746 | PO-073 Small non-coding RNA in serum from testicular germ cell tumour patientsidentified by machine learning |
| Q129589318 | PO-074 Metformin-induced apoptosis facilitates degradation of the C-FLIPL protein through a caspase-dependent pathway in human renal cell carcinoma A498 cells |
| Q129587380 | PO-075 Methanol fraction of calliandra portoricensis induces apoptosis and growth arrest in prostatic tumour cell lines |
| Q129587664 | PO-075 Study of the biomarker potential of long non-coding RNAs HULC in breast cancer |
| Q129587101 | PO-076 HMNQ induces apoptosis and autophagy dependent on reactive oxygen species through activation of JNK signalling pathway |
| Q129585906 | PO-076 Molecular analysis of BRCA-negative breast and/or ovarian cancer families by multigene panel testing |
| Q129585814 | PO-077 Identification of DHX30 as an inhibitor of the translation of pro-apoptotic mRNAS after P53 activation by nutlin |
| Q129588504 | PO-077 Tobacco use and cancer awareness among irula tribes, nilgiri hills, tamilnadu, india |
| Q129588007 | PO-079 Dysregulation of miR-196B in head and neck cancers leads to pleiotropic effects in the tumour cells and CAFs |
| Q129588413 | PO-079 Effect of a escin nano-formulation on human lung adenocarcinoma cells |
| Q129588002 | PO-080 Prevalence of human papilloma virus and its phylogenetic analysis in patients with head and neck squamous cell carcinoma in pakistan |
| Q129588824 | PO-080 V-ATPase G1 expression in human glioma stem cells correlates with ERK activation |
| Q129585769 | PO-081 Hypermethylation responses to inorganic arsenic exposure may increase the risk of liver cancer occurrence |
| Q129587087 | PO-081 Notch signalling pathway plays a crucial role in maintaining the cancer stem cell population in lung and colorectal cancer |
| Q129586206 | PO-082 BMP4-induced differentiation does not enhance chemosensitivity of glioma stem-like cells to temozolomide |
| Q129589240 | PO-082 Salivary extracellular vesicles from oral cancer patients: exclusive signature of the infrared spectrum |
| Q129586677 | PO-083 Suppressing the accumulation of cancer stem cells (CSC) using HDAC inhibitor reverses HNSCC chemoresistance by targeting NFKB signalling |
| Q129587923 | PO-083 The role of the humoral immune system in pancreatic cancer |
| Q129588498 | PO-084 Ascorbic acid selectively targets glucose metabolism of osteosarcoma stem cells |
| Q129585754 | PO-084 Familial risk of colorectal cancer in half-siblings similar to that in siblings |
| Q129589290 | PO-085 MiR-424(322)/503 regulates Wnt/b-catenin pathway and resistance to treatment in breast cancer |
| Q129586837 | PO-085 Mutational profiling can identify laryngeal dysplasia at risk of progression to invasive carcinoma |
| Q129586714 | PO-086 BCL11A interacts with SOX2 to control the expression of epigenetic regulators in lung squamous cell carcinoma |
| Q129588745 | PO-087 Oxidative stress as a selective anticancer agent: preclinical evaluation of a targeted combination strategy for mutant P53 non-small cell lung cancer |
| Q129588599 | PO-087 The WCRF/AICR third expert report on diet, nutrition, physical activity and cancer: updated recommendations |
| Q129588474 | PO-088 A modified electrochemical biosensor for sensitive detection of human chorionic gonadotropin (hCG) biomarker |
| Q129586727 | PO-089 135 Targeting treatment resistance in breast cancer subtypes via LMTK3 inhibition |
| Q129588204 | PO-089 The evidence on early growth and development and the risk of cancer by the WCRF/AICR continuous update project |
| Q129588770 | PO-090 Expression of the cocaine- and amphetamine-regulated transcript (CART) recruits SWI/SNF chromatin remodelling complexes to the oestrogen receptor |
| Q129589398 | PO-091 Droplet digital PCR based detection of aberrantly methylated genes in bile identifies cholangiocarcinoma in patients with primary sclerosing cholangitis |
| Q129588076 | PO-091 Induction of anti-Fas regulates PUMA and MYC: P53-dependent apoptosis pathway in hepatocellular carcinoma cells |
| Q129586856 | PO-092 Inhibition of the mTORC1-pathway can feedback-activate H-RAS or K-RAS |
| Q129587590 | PO-092 Sensitivity and specificity accurate of sniffing dogs to detect lung cancer |
| Q129587570 | PO-093 A hep-2 cell model as tool for analysing DNA double strand breaks in cancer patients |
| Q129588201 | PO-093 Lipocalin 2 suppress metastases of oral cancer through miRNA-29A-regulated dipeptidyl peptidase-4 |
| Q129587147 | PO-094 A novel prognostic significance of combination of preoperative systemic immune-inflammation index and monocyte-lymphocyte ratio in upper tract urothelial carcinoma |
| Q129586628 | PO-094 Persistent Myc activity prevents resolution of liver injury |
| Q129587563 | PO-095 ICOS: a crucial immunomodulator for development of immunotherapy |
| Q129586810 | PO-095 PIM kinases in the regulation of prostate cancer cell motility |
| Q129586512 | PO-096 Defining the role of Myc in the pancreatic cancer super enhancer network |
| Q129589334 | PO-096 Natural variation in serum small non-coding RNAs – potential biomarkers of cancer |
| Q129588934 | PO-097 Integration of data across toxicity endpoints to explore new ways for carcinogenicity safety assessment of chemicals |
| Q129586720 | PO-098 Peroxiredoxin II promotes hepatic tumorigenesis through cooperation with RAS/forkhead box M1 signalling pathway |
| Q129589068 | PO-098 Prevalence of head and neck cancers, and tobacco use among malayali tribes, yelagiri hills, tamil nadu, india |
| Q129586797 | PO-099 Age differences in coping strategies among patients with colorectal cancer |
| Q129586763 | PO-099 Targeting the mitogen activated protein kinase ERK5 in human melanoma |
| Q129587186 | PO-100 Targeting YAP and TAZ to treat hippo pathway mutant malignant mesotheliomas |
| Q129586718 | PO-101 P53 core domain activity at low PH |
| Q129589364 | PO-101 Relation between PSA level, its dynamics and performance of 18F-choline PET-CT in recurrent prostate cancer |
| Q129586662 | PO-102 Pre-diagnostic serum calcium concentrations and risk of colorectal cancer development in a prospective european cohort |
| Q129588854 | PO-102 Understanding the role of the tumour suppressor, FLCN, in renal tumorigenesis |
| Q129589055 | PO-103 Can we eat to prevent colorectal cancer? |
| Q129589469 | PO-103 Regulation of prostate cancer cell growth and signalling by exercise |
| Q129589084 | PO-104 Role of the oncosuppressor CTCF in the erythroid cell differentiation and regulation of erythroid genes |
| Q129585982 | PO-105 CDH3/P-cadherin as a novel biomarker in glioblastoma: functional and prognostic insights |
| Q129587299 | PO-106 Downregulation of MYPT increases tumorigenesis and resistance to platin drugs in ovarian cancer |
| Q129588084 | PO-106 Unique and overlapping role of HIF proteins in radiation response and tumour cell metabolism |
| Q129588626 | PO-107 A potential role for DELTA40P53 in the regulation of breast cancer stem cells |
| Q129586601 | PO-107 Notch signalling pathway is required for proliferation, repair and differentiation of primary human lung stem cells upon irradiation |
| Q129586009 | PO-108 FKBP10 is an oncofetal protein that supports lung cancer growth by promoting protein translation elongation |
| Q129586716 | PO-108 Nonstandard hypofraction radiotherapy in neoadjuvant chemo-radiation therapy in treatment of locally advanced rectal cancer |
| Q129588560 | PO-109 Integral membrane protein 2A expression leads to enhanced anti-cancer effects and chemosensitivity in epithelial ovarian cancer |
| Q129587305 | PO-109 Particle therapy reduces weight loss and toxicities among patients with head and neck cancer |
| Q129588541 | PO-110 AKT expression is associated with poor clinical outcome in ovarian cancer |
| Q129587458 | PO-110 Targeted alpha-therapy for gastric cancer metastasized to liver in mice |
| Q129589310 | PO-111 Capicua suppresses hepatocellular carcinoma progression by controlling ETV4-MMP1 axis |
| Q129589156 | PO-111 Non-contact electric fields inhibit the growth of breast cancer cells in animal models and induce local immune reaction |
| Q129588679 | PO-112 The role of transcribed ultraconserved regions Uc160 and Uc346 in colorectal cancer progression |
| Q129586081 | PO-112 The senescence associated secretory phenotype (SASP)-factor CcL2 fosters vascular dysfunction and endothelial cell loss in radiation-induced lung disease |
| Q129587140 | PO-113 Investigation of the role of IRF4 in melanoma cells |
| Q129588631 | PO-113 PARP-1 depletion in combination with either high or low LET reduces the metastatic potential in cultured human cells by suppression of its MMP activity |
| Q129587266 | PO-114 Histone deacetylase 6 regulates NOTCH3 endosomal trafficking and degradation in T-cell acute lymphoblastic leukaemia cells |
| Q129589325 | PO-114 Overexpression of miR-205–3 p increases sensitivity to low-dose ionising radiation in DLD-1 cells |
| Q129588803 | PO-115 HER2-amplified tumours overcome the requirement for HER3 |
| Q129586094 | PO-115 Radiation resistance mechanisms of breast cancer cells |
| Q129587922 | PO-116 Increase in prothymosin alpha expression with histological aggressiveness of glioma |
| Q129589189 | PO-116 Indium-111 afterloading of preformed EGF-containing liposomes for molecularly targeted radionuclide delivery via ultrasound-induced cavitation |
| Q129589066 | PO-117 Increased risk of in utero x-ray exposure to mice treated with n-ethyl-n-nitrosourea postnatally |
| Q129587138 | PO-117 Role of NFE2L3 in colon cancer by regulating cancer cells proliferation |
| Q129588688 | PO-118 Impact of parity on neutron-induced mammary cancer risk in sprague-dawley rats |
| Q129587234 | PO-118 The expression of the calcium-sensing receptor in colon organoids |
| Q129589200 | PO-119 Accelerated glutamine metabolism is conferring radioresistance to prostate cancer |
| Q129587400 | PO-119 Ferritin heavy subunit enhances apoptosis of non-small cell lung cancer cells through modulation of a miR-125B/P53 axis |
| Q129588191 | PO-120 Metastatic breast cancer: underlying molecular mechanisms of radiation response |
| Q129586229 | PO-120 Proline rich homeodomain protein is required for cholangiocarcinoma tumour growth |
| Q129585994 | PO-121 ALK dependant phosphoproteome and gene expression profiling of neuroblastoma cells |
| Q129589197 | PO-121 Lentivirally-delivered ShRNA knockdown of CXCL12 prevents fibrosis in a rodent model of radiation late adverse effects |
| Q129588527 | PO-122 Synemin is a novel co-regulator of non-homologous end joining in head and neck cancer cells |
| Q129588074 | PO-123 Constitutive expression of FAT1 gene inhibits the invasion and tumorigenicity of cervical cancer cells through degradation of HPV E6/E7 oncoprotein via P53/RB in vitro and in vivo |
| Q129589333 | PO-124 MIR-1246 mediates crosstalk between DNA damage repair and the ups in autophagy to regulate the sensitivity of non-small cell lung cancer to radiation |
| Q129587100 | PO-124 PTTG and PBF functionally interact with P53 and predict overall survival in head and neck cancer |
| Q129585890 | PO-125 FAT1 on salvador-warts-hippo (SWH) pathway in human glioblastoma |
| Q129588633 | PO-125 Role of NRF2 in breast cancer stem cells resistance and tumourrecurrence |
| Q129586782 | PO-126 Exploration of novel regulators of mutant P53 |
| Q129587261 | PO-126 Survival probability of human breast carcinoma cells to radiation treatment: role of cell fusion and of a syncytin1-homologous protein |
| Q129587938 | PO-127 Investigating the response of normal and cancer bladder cells to radiotherapy |
| Q129586242 | PO-127 Role of the NEDD4 family of E3 ubiquitin ligases in colorectal cancer pathogenesis and their potential as biomarkers |
| Q129588609 | PO-128 Identification of the E3 ubiquitin ligase ITCH as a novel regulator of connexin 43 degradation and gap junction intercellular communication |
| Q129586845 | PO-128 MicroRNA-449A enhances the radiosensitivity of prostate cancer cells |
| Q129586798 | PO-129 In vitro radiosensitivity and repair kinetics of PBMCs from prostate cancer patients and healthy donors evaluated by comet assay |
| Q129586680 | PO-129 Transfection with liver-type glutaminase (GAB) sensitiseshuman glioblastoma cell lines to hydrogen peroxide by downregulation of the PI3K/AKT pathway |
| Q129586211 | PO-130 SER235 residue drives eIF6 oncogenic activity in NPM-ALK induced T cell lymphomagenesis |
| Q129588119 | PO-131 Over expression of extracellular matrix protein 1 (ECM1) in muscle-invasive bladder cancer |
| Q129588520 | PO-131 Reprogramming of cancer cell metabolism by adaptation to chronic cycling severe hypoxia increases radiation resistance |
| Q129587892 | PO-132 Alpha5 beta1 integrin provides glioma cell resistance to EGFR tyrosine kinase inhibitors. role of membrane trafficking |
| Q129589272 | PO-132 Dissecting the radiobiology of targeted radionuclide therapy reveals an intra-tumoral heterogeneic response in a preclinical in vivo model |
| Q129588494 | PO-133 Hoxa9 transcription factor: a potential novel therapeutic target in renal cell carcinoma (RCC) |
| Q129589269 | PO-134 Cytogenetic and molecular characterisation of new high-grade serous ovarian cancer cell line OVPA8 |
| Q129587401 | PO-134 Radiosensitizing effect of gold-based nanoparticles for brain tumourtreatment |
| Q129587953 | PO-135 Analysis of the transforming activity of human cancer identified Vav1 mutants prove its classification as an oncogene |
| Q129586079 | PO-135 GEF-X is an independent prognostic factor of gastric cancer associated with cancer stem cell development and radioresistance using multi-omics data |
| Q129588859 | PO-136 SOX2 is a novel biomarker for high-risk ewing sarcoma |
| Q129587444 | PO-136 Studying pathway interactions and dynamics to predict cell responses to chemotherapeutic treatment in breast cancer cells |
| Q129588694 | PO-137 Computational metabolism modelling predicts risk of relapse in breast cancer patients |
| Q129587419 | PO-137 Liver specific NEMO ablation induces mixed hepatocellular-cholangiocarcinoma in MYC-overexpressing mice |
| Q129586872 | PO-138 Dimethyl fumarate modulation of antioxidant response in cancer cells: therapeutic applications |
| Q129588537 | PO-138 Hedgehog signalling pathway activity in high-grade serous ovarian carcinoma |
| Q129585855 | PO-139 Identify rational drug combinations for triple negative breast cancer by integrative network modelling |
| Q129589106 | PO-139 Investigating unusual synthetic lethalgenes in acute lymphoblastic leukaemia |
| Q129586795 | PO-140 Cellular localization of survivin influences the response of colorectal cancer cells to topoisomerase I inhibitors |
| Q129585830 | PO-141 FAT1 acts as an oncogene and regulate the expression of miR-221/222–3 p in glioblastoma |
| Q129586020 | PO-141 The onocogenic kinase Pim2 as target in hepatocellular carcinoma |
| Q129586078 | PO-142 RNAi-mediated therapeutic knockdown of the neuropilin axis and GIPC1 in pancreatic carcinoma |
| Q129586852 | PO-143 Frequent loss of annexin A1 expression in head and neck squamous cell carcinomas by transcriptional regulatory mechanisms |
| Q129588756 | PO-143 Recurrent transcriptional remodelling events represent clinically actionable targets in breast cancers brain metastasis |
| Q129585981 | PO-144 HGF/c-met signalling pathway downregulates lncRNA HOTAIR to induce adhesion independent growth in HCC by increasing caveolin-1 expression |
| Q129587210 | PO-144 Role of increased expression of brain and acute leukaemia, cytoplasmic (BAALC) in acute myeloid leukaemia (AML) DNA damage repair pathways |
| Q129589315 | PO-145 ERK5 pathway inhibitors inhibit the maintenance of chronic myeloid leukaemia stem cells |
| Q129588653 | PO-146 Knockout validation of antibodies to components of the NF-kB signalling pathway |
| Q129589296 | PO-146 Multiple myeloma-derived exosomes carry amphiregulin and are responsible for the uncoupled bone remodelling |
| Q129587224 | PO-147 Pinostilbene hydrate suppresses human oral cancer cell metastasis via downregulation matrix metalloproteinase-2 through the mitogen-activated protein kinase signalling pathway |
| Q129585969 | PO-148 Activin a upregulation mediated by P63 promotes migration and invasion of oral cancer cells |
| Q129589185 | PO-148 Suppression of carnosine on adhesion and extravasation in human colorectal cells |
| Q129589052 | PO-149 Expression profiling of TP53, TP73, NME and GLI families of genes/proteins in metastatic melanoma |
| Q129589384 | PO-149 Vimentin in epithelial cancer cells during adaptation to the growth in vitro |
| Q129586838 | PO-150 Modulation of the expression of casein kinase i isoform alpha in the initiation and progression of prostate cancer |
| Q129586678 | PO-150 Tomatidine inhibits human osteosarcoma cells metastasis by down-regulation of presenilin-1 and the Raf/MEK/ERK pathway |
| Q129588790 | PO-151 Notch signalling differentiates disease-free survival in prostate cancer patients by affecting the epithelial-to-mesenchymal transition-associated processes |
| Q129589150 | PO-151 Variation of ribosome composition and translational reprogramming during human mammary epithelial-to-mesenchymal transition |
| Q129587883 | PO-152 Differentiation of lung squamous cell carcinoma (LUSC) and lung adenocarcinoma (LUAD) by gene co-expression analysis of notch signalling targets |
| Q129587291 | PO-153 Investigating tobacco smoking differential effects on lung and bladder cancer |
| Q129586539 | PO-153 SOX9 regulates epithelial to mesenchymal transition and self-renewal in pancreatic adenocarcinoma promoting metastasis and chemoresistance |
| Q129588310 | PO-154 Gene expression profile in tumour cells exposed in vitro to photodynamic therapy with a novel porphyrinic compound |
| Q129586814 | PO-154 Progesterone through progesterone receptor-B inhibits invasion of human breast cancer cells by targeting cytoplasmic cyclin D1 |
| Q129586570 | PO-155 Study of the effect of pentraxin 3 on the metastasis-related protein of human osteosarcoma cell lines |
| Q129588784 | PO-155 Therapeutic evaluation of HEDGEHOG-GLI signalling pathway through miRNA and mRNA profiling of ovarian carcinoma |
| Q129586697 | PO-157 Estimation of functional effector genes reveals disease mechanisms in breast cancer in very young women |
| Q129586574 | PO-158 Extracellular vesicles, generated from UVA-exposed melanoma cells, promotes cell proliferation and invasion |
| Q129587216 | PO-158 Induction of interferon signalling by natural DNA-binding compounds with cancer preventive activity |
| Q129588825 | PO-159 Deciphering the function of endogenous E-cadherin glycosylation during ovarian cancer spread |
| Q129588743 | PO-159 Expression profiles of P53/P73 isoforms in human melanoma cell lines |
| Q129586589 | PO-160 Downregulation of the oncofetal gene SALL4 in melanoma leads to invasion and metastasis by differential acetylation mediated through binding to HDACs |
| Q129589098 | PO-160 Investigation of ubiquitin-ligase HUWE1 in the modulation of RAS pathway in leukaemia models |
| Q129587205 | PO-161 Cancer cell migratory phenotype characterisation on IGDQ-expressing surface |
| Q129589229 | PO-161 The AMPK and MEK/ERK signalling pathways regulate mitochondrial FOXO3A import through phosphorylation of serine 12 and serine 30 |
| Q129588025 | PO-162 Long non coding RNA H19 (IncH19) is required for the hypoxia mediated multiple myeloma progression |
| Q129586728 | PO-162 The transcription factor GATA4 is overexpressed in malignant meningioma enhancing proliferation via downregulation of miR-15 family members |
| Q129589266 | PO-163 Identification of candidate genes underlying soft tissue sarcoma progression using a progression series of murine fibrosarcoma cell lines |
| Q129586026 | PO-163 Junctional adhesion molecule-a is a novel upstream regulator of human epidermal growth factor receptor-3 signalling in breast cancer |
| Q129588782 | PO-164 Modulation of EGFR to overcome tumour resistance and improve radiotherapy response in HPV positive and negative head and neck cancer cells |
| Q129586018 | PO-165 Effect of notch pathway and Skp2 inhibition in cell viability/proliferation of medulloblastoma cells |
| Q129588030 | PO-165 Estetrol reduce cell migration and proliferation in two/three-dimensional T47D breast cancer cell model |
| Q129586025 | PO-166 Polyol pathway connects glucose metabolism with cancer differentiation and EMT |
| Q129589246 | PO-166 The expression of nicotinate nucleotide pyrophosphorylase is elevated in colorectal cancer tissues |
| Q129586659 | PO-167 Metabolomics biomarkers in breast cancer tumours treated with neoadjuvant therapy |
| Q129586839 | PO-167 MicroRNA- 200 c, a tumour suppressor that modulate the expression of cancer stem cells markers and epithelial-mesenchymal transition in colorectal cancer |
| Q129588069 | PO-168 IKBKE regulates TSC1 for the activation of mTOR/S6K pathway in tumour cells |
| Q129587197 | PO-168 Loss of the MCC gene expression promotes invasiveness of colon cancer cells |
| Q129585801 | PO-169 Involvement of neurotensin and neurotrophins pathways in human colorectal cancer cells 5-fluorouracil treatment resistance |
| Q129585162 | PO-169 Rethinking the EGF-mediated tensin switch in colorectal cancer |
| Q129585737 | PO-170 A Suv39H1-low chromatin state drives migratory cell populations in cervical cancers |
| Q129586623 | PO-170 Dissecting the role of IFITM1 in response to anticancer treatment |
| Q129588065 | PO-171 Identifying IFITM1-dependent synthetized proteins in interferon gamma stimulated cells |
| Q129587863 | PO-171 Tissue specific extravasation and invasion of MDA-MB-231 cells in a lab-on-a-chip system |
| Q129586197 | PO-172 Role of lithocholic acid-induced cell signalling in oesophageal cancer progression model |
| Q129589103 | PO-173 Critical requirement of the Sos1 and Sos2 RasGEFs for maintenance of mitochondrial homeostasis |
| Q129589058 | PO-173 Sialylation of integrin alpha 2 promotes ovarian cancer cells metastasis |
| Q129589450 | PO-174 ErbB2 glycosylation landscape in gastric cancer cells – a novel functional target? |
| Q129588651 | PO-174 Evaluation of immunohistochemical expression of microfibrillar-associated protein 5 (MFAP5) in invasive breast carcinoma of no special type |
| Q129585796 | PO-175 Effects of trastuzumab and afatinib on kinase activity in gastric cancer cell lines |
| Q129589201 | PO-175 The secretary miR-141 facilitates ovarian cancer metastasis through reprogramming stromal fibroblast cells in pre-metastatic niches formation |
| Q129586647 | PO-176 Hepatocyte growth factor activator inhibitor-2 suppresses human prostate and lung cancer cell invasion and metastasis |
| Q129588468 | PO-177 New targets in triple negative breast cancer: role of oncostatin m receptor pathway |
| Q129586221 | PO-177 The novel function of DUSP2/VEGF-C axis in pancreatic cancer progression |
| Q129586356 | PO-178 Androstenedione (4AD) activates an androgen receptor (AR) mediated transcriptome and AR interactions associated with cell-cell adhesion in aromatase inhibitor (AI) resistant breast cancer cells |
| Q129588130 | PO-178 WDR5 promotes metastasis dissemination in breast cancer |
| Q129587292 | PO-179 Breast cancer cells and macrophages in a paracrine-juxtacrine loop |
| Q129589293 | PO-179 Identification of C-Met and insulin receptor heterodimer as a mediator for hepatocellular carcinoma |
| Q129589105 | PO-180 Dissecting the effects of EGF starvation on EGFR signalling in the mouse small intestine using 3D organoid culture systems |
| Q129587165 | PO-180 Transforming growth factor beta 1activates cell migration through the down-regulation of PRH/HHEX expression |
| Q129587541 | PO-181 Anaplastic lymphoma kinase addictive neuroblastoma cell lines are associated with growth upon treatment with MEK inhibitor trametinib |
| Q129586792 | PO-181 Predicting homing ability of hepatocellular carcinoma cells by using a lab-on-a-chip system |
| Q129589307 | PO-182 Examining the function of PDGFRB in anaplastic large cell lymphoma |
| Q129589176 | PO-182 The upregulation of EPDR1 is related to tumour invasiveness in a cohort of localised colorectal cancer patients |
| Q129586717 | PO-183 Identification of differentially hypomethylated genes associated to metastasis behaviour in colorectal cancer |
| Q129585823 | PO-183 Prolactin activation of JAK2/STAT3 signalling pathway through GHR in NSCLC |
| Q129587411 | PO-184 Proteomic profiling to predict response towards therapeutic monoclonal antibodies in HER2 low breast cancer |
| Q129588503 | PO-184 Role of ubiquitin-conjugating enzymes in chromosome instability and breast cancer metastasis |
| Q129589298 | PO-185 Non-canonical S727 STAT3 PTM activation governs its dimerization and downstream function in triple negative breast cancer |
| Q129586695 | PO-186 Generation of the GLI1, GLI2 and GLI3 knock-out ovarian cancer cell lines using the CRISPR/Cas9 |
| Q129587348 | PO-186 In vitro and clinical studies of the role of MHC class II invariant chain (CD74) in breast cancer |
| Q129588512 | PO-187 Defective liver regeneration ability of Sos1-KO and Sos1/2-DKO, but not Sos2-KO mice |
| Q129587104 | PO-187 Liquid-phase polarity facilitates attachment, adhesion and metastasis of tumour cells |
| Q129586038 | PO-188 Loss of uPAR function and suppression of malignant cell behaviour by a GPI-specific phospholipase C |
| Q129588759 | PO-189 Optimisation of a lab-on-a-chip device and method for quantification of extravasation |
| Q129588022 | PO-190 In silico and in vitro screening of polyphenolic compounds for their mTOR modulatory capacity |
| Q129585939 | PO-191 Effects of non-canonical activation of protease-activated receptor 1 (PAR1) in melanoma cell lines |
| Q129588705 | PO-192 The EMT factor zeb1 promotes adenoma formation through the inhibition of cell senescence and apoptosis |
| Q129586147 | PO-193 The effect of chemotherapy induced intercellular communication on breast cancer metastasis |
| Q129586591 | PO-194 Identification of regulatory circuits specific to breast cancer development by enrichment based circuit finder |
| Q129585808 | PO-195 Integrative analysis of in vivo models of pancreatic cancer reveals complex mechanisms behind treatment failure and provides new tools for effective targeting |
| Q129588657 | PO-195 Investigation of the roles of CD90 protein in cell migration, invasion, and colony-forming ability of cancer cells |
| Q129585877 | PO-196 Identification of novel molecular players of GBM cell dispersal through an in vitro profiling approach |
| Q129587572 | PO-196 Vav1 and Mutant K-Ras synergize in pancreatic ductal adenocarcinoma development: lessons from mouse models |
| Q129586089 | PO-197 A possible link between the mitochondrial gatekeeper pyruvate dehydrogenase enzyme complex and EMT |
| Q129586796 | PO-197 Patient-derived xenograft (PDX) models of glioblastoma: from basic research to preclinical studies |
| Q129587901 | PO-198 Flavopereirine suppresses colorectal cancer growth via inducing cell cycle arrest and apoptosis in P53 signalling dependence |
| Q129586006 | PO-199 Lysyl oxidase in head and neck cancer: metastasis and therapy response |
| Q129588725 | PO-199 Platelet aggregate formation in a novel murine preclinical glioma model depends on podoplanin expression on tumour cells |
| Q129589445 | PO-200 3D In vitro cultures of PDX-derived tumour for anti-cancer drug discovery |
| Q129589452 | PO-200 Prevention of melanoma brain colonisation by inhibiting cytokines secretion from activated astrocytes |
| Q129589243 | PO-201 Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase |
| Q129588764 | PO-201 NF1 inhibits glioma cells invasion and reverts mesenchymal transition |
| Q129587908 | PO-202 PI3K activation in neural stem cells drives tumourigenesis which can be ameliorated by targeting the cAMP response element binding (CREB) protein |
| Q129586803 | PO-202 The role of RhoG in migration and invasion of astrocytoma cells |
| Q129586700 | PO-203 Peroxiredoxin 5 in colon cancer promotes epithelial-mesenchymal transition |
| Q129587207 | PO-204 The contribution of epithelial to mesenchymal transition (EMT) to the metastases of pancreatic cancer |
| Q129588946 | PO-204 Vascular effects of targeted photodynamic therapy of human glioblastoma with theranostic AGuIX nanoparticles |
| Q129589303 | PO-205 Characterisation of the integrin alpha v-dependent adhesome in mda-mb-435s melanoma cells |
| Q129589196 | PO-205 Functional characterisation of BRIP1/FANCJ in tumour suppression and therapy response |
| Q129586012 | PO-206 Calponin 3 (CNN3) promotes epithelial to mesenchymal transition and drug resistance of colon cancer cells |
| Q129586866 | PO-206 Modelling T cell acute lymphoblastic leukaemia using CRISPR/Cas9 mediated genome editing in Xenopus tropicalis |
| Q129589435 | PO-207 Ferritin-engineered nanoparticles as targeted drug delivery system for cancer treatment |
| Q129588641 | PO-207 The role of RSU-1 in glioma cells metastasis |
| Q129587412 | PO-208 Emerging roles of HECT type E3 ubiquitin ligase smurf2 in cancer |
| Q129588148 | PO-208 Human zebrafish xenografts as therapy sensors for breast cancer |
| Q129587273 | PO-209 Biological characterisation of specific KRAS mutations: from basic biology to response to treatment |
| Q129586740 | PO-209 CRISPR/Cas9 based development of RNAi rat models for drug discovery |
| Q129588262 | PO-210 Anticancer drug-induced senescence in glioblastoma cells is associated with changes in DNA repair capacity |
| Q129588031 | PO-210 Synergy between the KEAP1/NRF2 and PI3K pathways drives non-small cell lung cancer with an altered metabolism |
| Q129587418 | PO-211 KRAS driven lung adenocarcinoma depends on ERBB signalling |
| Q129586543 | PO-211 Profiling the alternative splicing landscape of senescent cells |
| Q129589270 | PO-212 Morphological heterogeneity of hepatosplenic gamma/delta T-cell lymphoma |
| Q129589301 | PO-213 High glucose affects ER +breast cancer cell metabolism |
| Q129588534 | PO-213 Sigma receptors: development of novel therapeutic approaches in pancreatic cancer |
| Q129589100 | PO-214 Combination of molecular hydrogen (H2) and 5-FLUOROURACIL (5-FU) in cancer treatment |
| Q129587477 | PO-214 Conditional control of MITF reveals cellular subpopulations essential for melanoma survival and recurrence in new zebrafish models |
| Q129586528 | PO-215 Patient-derived and cell line xenograft growth in the B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd (R2G2) mouse model |
| Q129588117 | PO-215 Resistance to retinoids – analysis of putative biomarkers in neuroblastoma cells and tumour tissue samples |
| Q129589335 | PO-216 Chemotherapeutic tolerability and oestrogen dose response in the B6;129-Rag2tm1FwaIL2rgtm1Rsky/DwlHsd (R2G2) mouse model |
| Q129589418 | PO-216 Metabolic and molecular programming induced due to hyperglycemia in breast cancer |
| Q129588033 | PO-217 Loss of Kmt2c methyltransferase activity contributes to prostate tumorigenesis in a mouse model of prostate cancer |
| Q129585907 | PO-217 Tumour suppressor function of the oxidoreductase p66Shc in BRAFV600E-transformed cells |
| Q129587878 | PO-218 Cytokine-transgenic NOG mice engrafted with human peripheral blood cells support natural killer cell expansion |
| Q129589417 | PO-218 MicroRNA in mitochondria of multidrug resistant hepatocellular carcinoma |
| Q129586833 | PO-219 Methylglyoxal-induced dicarbonyl stress: role in melanoma progression and response to therapy |
| Q129587301 | PO-219 New cell genetic tracing and single-cell tools for the study of the molecular pathways involved in cancer metastasis |
| Q129588038 | PO-220 Defining the role of heparanase in breast cancer progression using the PyMT-MMTV mouse model |
| Q129588528 | PO-220 RAN, a novel and promising gene for malignant pleural mesothelioma |
| Q129589222 | PO-221 Mouse models of lung squamous cell carcinoma for preclinical intervention studies |
| Q114978891 | PO-221 Prostate cancer cells are able to use fructose as a metabolic source |
| Q115036812 | PO-222 Molecular characterisation of low grade lymphoma in northern sea otters (Enhydra lutris kenyoni) |
| Q129587407 | PO-222 Targeting cancer cell metabolism in melanomas: metabolic profiling and 3-bromopyruvate sensitivity screening |
| Q129586865 | PO-223 Modelling malignant mesothelioma in mice: a critical role for BAP1 loss |
| Q129587574 | PO-224 Fourier transform infrared spectroscopy-based detection of hypoxia-induced biomolecular changes in different cancer cell lines |
| Q129587862 | PO-224 consequences of FOXP1-mediated transcriptional repression of the mitotic checkpoint gene MAD2 in breast cancer |
| Q129588023 | PO-225 Dual role of methylglyoxal, a glycolysis side-product, in cancer |
| Q129587387 | PO-226 Dicarbonyl stress induces ECM remodelling and MAPK signalling activation in metastatic breast cancer cells |
| Q129587890 | PO-226 Integrated analysis highlights APC11 protein expression as a likely new independent predictive marker for colorectal cancer |
| Q129586016 | PO-227 Sensitising glioma cells to fatty acid oxidation inhibitor by modulation of SLC22A5 transporter activity |
| Q129586554 | PO-227 The effect of chronic mild hypoxia on genomic instability in HER2-overexpression breast cancer cell line SK-BR-3 |
| Q129588715 | PO-228 Comprehensive molecular characterisation of TNBCs expressing HORMAD1, a driver of homologous recombination deficiency |
| Q129588101 | PO-228 Regulation of GDE2 membrane localization and trafficking |
| Q129588086 | PO-229 The fatty acid desaturase SCD1 as crucial factor for tumour progression in colon cancer |
| Q129589434 | PO-229 Transient tissue ‘priming’ via FAK inhibition to impair pancreatic ductal adenocarcinoma (PDAC) progression to improve sensitivity to gemcitabine/abraxane |
| Q129587313 | PO-230 Cysteine-rich secretory protein 3 regulates progression from in situ to invasive prostate cancer |
| Q129589111 | PO-230 Effect of C. cochinchinense extract on V-ATPase inhibition triggering apoptosis in human cancer cell lines |
| Q129586650 | PO-231 CTXIII expression around single tumour cells of invasive breast carcinoma |
| Q129585849 | PO-231 mTOR activity differences and related metabolic activity in human breast cancer cell lines |
| Q129587382 | PO-232 Actin-dependent effect of tumour suppressor P53 on human lung cancer cell malignant characteristics |
| Q129588677 | PO-232 Lewis glycans and their epigenetic regulation are associated with neuroblastoma aggressiveness |
| Q129586239 | PO-233 Chemoresistant NSCLC cells are hypersensitive to metabolic drugs due to mTOR-mediated inhibition of autophagy |
| Q129588519 | PO-233 DOCK1 as a novel molecular target for controlling cancer cell survival and invasion |
| Q129586582 | PO-234 Transwell co-culture with human breast adipocytes alters the proteome expression profiles of MCF-7 and MDA-MB-231 human breast cancer cells |
| Q129587333 | PO-235 Fenofibrate overcomes the drug-resistance of human prostate cancer cells |
| Q129586024 | PO-235 Integrin beta-like 1 overexpression stimulates invasiveness of ovarian cancer cells in vitro |
| Q129586898 | PO-236 Human ligase profiling to predict platinum sensitivity and clinical outcome in primary epithelial ovarian cancers |
| Q129588471 | PO-237 Neutralising extracellular morgana impairs breast tumour growth and migration |
| Q129587375 | PO-237 The pro-oncogenic transcription factor STAT3 regulates Ca2 +release and apoptosis from the endoplasmic reticulum via interaction with the Ca2 +CHANNEL IP3R3 |
| Q129588044 | PO-238 Clinicopathological significance of EMT markers in thymic epithelial tumours |
| Q129586136 | PO-238 Dichloroacetate (DCA) treatment affects mitochondrial activity and stemness in pancreatic cancer (PC) cell lines |
| Q129586291 | PO-239 Benzo(a)pyrene, an active product of cigarette smoke, role in PLA2 isoforms activation in colon cancer |
| Q129587456 | PO-239 Towards identifying key drivers of breast cancer metastasis to the bone |
| Q129589309 | PO-240 Targeting cancer stem cells in mammary triple negative cell line by retinoids and lapatinib treatments |
| Q129588684 | PO-240 WWOX suppressor gene regulate glucose metabolism and warburg effect in case of gestational diabetes mellitusas well as breast cancer |
| Q129588628 | PO-241 Prognostic factors for operable biliary tract cancer: serum levels of lactate dehydrogenase: a strong association with survival |
| Q129586643 | PO-241 Targeting fatty acid oxidation and glycolysis to overcome drug resistance to MAPK inhibitors |
| Q129588040 | PO-242 Myoferlin controls mitochondrial structure and metabolism in pancreatic ductal adenocarcinoma, and affects tumor aggressiveness |
| Q111491250 | PO-242 Novel analysis of cancer cell invasion using a three-dimensional cultured tissue model mimics human tissue organisation |
| Q129588761 | PO-243 Exosomes from plasma of HNSCC patients treated with photodynamic therapy are biomarkers for epithelial-mesenchymal transition |
| Q129586120 | PO-243 Uncoupling FOXO3A mitochondrial and nuclear functions in cancer cells undergoing metabolic stress and chemotherapy |
| Q129586609 | PO-244 Catechol-O-methyltransferase: a dual-role player in different breast cancer subtypes? |
| Q129588500 | PO-245 Fructose supports tumour growth and aggressiveness through a metabolic reprogramming in prostate cancer |
| Q129587584 | PO-245 Vimentin expression as a sign of epithelial-mesenchymal transition in prostate cancer |
| Q129588836 | PO-246 AXL receptor tyrosine kinase expression as a prognostic marker and therapeutic target in neuroendocrine tumours |
| Q129588118 | PO-246 Nandrolone affects cell growth and differentiation in hepatoma cells |
| Q129587919 | PO-247 Mesothelin regulates invasion and peritoneal metastization of ovarian cancer |
| Q129588258 | PO-248 Novel insights on the role of glycosylation in cancer: molecular functions and clinical applications |
| Q129586696 | PO-248 The role of ER stress in arginine deprivation-induced radiosensitization and cell death of HNSCC cells |
| Q129588108 | PO-249 GLUL knockdown induces drug resistance in non-small cell lung cancer cells |
| Q129588721 | PO-249 Phylogenetic relationships between paired primary papillary thyroid carcinomas and distant metastasis: intra-tumour molecular heterogeneity and clonal evolution |
| Q129587349 | PO-250 Investigating BRF2-dependent RNA polymerase III transcription deregulation in cancer |
| Q129589383 | PO-250 Phospho S82 Hsp27: a marker of invasive and recurrent non-functioning pituitary adenoma |
| Q129588170 | PO-251 High density fibrillar collagen promotes breast cancer cell invasion by decreasing actin dynamics at invadopodia |
| Q129587397 | PO-251 Modulation of NAD+levels by NQO1 enzymatic action alleviates adriamycin-induced cardiac dysfunction in mice |
| Q129585806 | PO-252 Impaired glucose metabolism in human glioma stem cells upon treatment with a cell-penetrating peptide based on CONNEXIN43 |
| Q129586533 | PO-252 The circuit of oncofetal O-glycosylation, galectin-4, RTK, and MYC drives metastatic castration-resistant prostate cancer |
| Q129589113 | PO-253 Characteristics of cellular respiration, glycolytic activity and related metabolic features in wild type and IDH1 mutant glioma cells |
| Q129586553 | PO-254 G protein-coupled oestrogen receptor activation decreases prostate cancer cells viability concomitantly with altered proliferation, apoptosis, and metabolic profile |
| Q129588649 | PO-254 Merkel cell polyomavirus T-antigen regulate microRNAs post-transcriptionally through DICER in merkel cell carcinoma |
| Q129585881 | PO-255 The pivotal role of glutaminolysis in prostate cancer cells and its regulation by androgens |
| Q129588488 | PO-255 The role of solid stress in tumor-stromal interactions |
| Q129589198 | PO-256 The extracorporeal immunopharmacotherapy (EIPHT) and remote results of cervical cancer and ovarian cancer treatment |
| Q129587413 | PO-257 Loss of the mitochondrial pyruvate carrier drives ‘glutamine addiction’, a hallmark of aggressive ovarian cancers |
| Q129586144 | PO-257 The immunoreactivity of patients with cervical cancer on the background of extracorporeal immunopharmacotherapy (EIPHT) |
| Q129588535 | PO-258 Can we treat early breast cancer without surgery? Is primary definitive hormone therapy a valid alternative for operable hormone sensitive breast cancer? |
| Q129589365 | PO-258 Telmisartan induces melanoma cell apoptosis via generation of ROS and has synergistic effects with targeted therapy in vitro |
| Q129586521 | PO-259 Identification of a clinically meaningful site-specific steroid roadmap in prostate cancer |
| Q129588026 | PO-259 Inhibition of the hexosamine biosynthetic pathway by targeting PGM3 causes breast cancer growth arrest and apoptosis |
| Q129587920 | PO-260 Anti-lymphoma activity of novel selective glucocorticoid receptor agonists (SEGRAs) in vitro and in vivo |
| Q129589220 | PO-260 Deep phenotyping of colorectal cancers by high-dimensional mass cytometry reveals tumor-specific immune landscapes |
| Q129588112 | PO-261 Multimodal mass spectrometry imaging to understand drug delivery, metabolism, response and amp; resistance in pancreatic ductal adenocarcinoma |
| Q129589439 | PO-261 Subcellular localization and expression of NME6, a member of the NME/Nm23/NDPK family, in human tumour cells |
| Q129587452 | PO-262 Differential expression of Sphingosine-1-Phosphate metabolising enzymes in oral squamous cell carcinoma |
| Q129644194 | PO-262 Remodelling of the tumour microenvironment by pegvorhyalurondiase alfa (PEGPH20): a novel, first-in-class biologic that enzymatically degrades tumour hyaluronan (HA) to improve anti-tumour efficacy |
| Q129586585 | PO-263 Assessment of the accumulation of hyaluronan in the tumour microenvironment (TME) of solid tumours |
| Q129586901 | PO-263 Epigenetic modulation of cell metabolism and its effects on cell survival in melanoma |
| Q129589051 | PO-264 Mitochondrial metabolism: a key factor of myeloid leukemic cell response upon exposure to tyrosine kinase inhibitors |
| Q129588110 | PO-264 Preclinical studies with pegvorhyaluronidase alfa (PEGPH20) in combination with FOLFIRINOX (FFX) chemotherapy in models of pancreatic ductal adenocarcinoma |
| Q129586694 | PO-265 Cisplatin induces pro-inflammatory program and modulates pro-angiogenic potential of human tumor-associated macrophages |
| Q129588709 | PO-266 Metabolic profiling of osteosarcoma cancer stem cells as tool to identify potential target for cancer therapy |
| Q129588744 | PO-267 Notch-dependent tumourigenic mechanism associated with exosome signalling |
| Q129587416 | PO-267 PHGDH and PSAT confer metabolic vulnerability to IDH2-driven reprogramming in breast cancer |
| Q129588522 | PO-268 Adipose-derived mesenchymal stem cells microenvironment promotes the tumorigenic phenotype in triple negative breast cancer cell line |
| Q129587931 | PO-268 The interaction of hERG1 potassium channels with integrin receptors perturbs the force transduction machinery in pancreatic cancer |
| Q129589405 | PO-269 Development of a fluorescence in situ hybridization (FISH) method for detection of intra-tumour bacteria involved in pancreatic cancer chemoresistance |
| Q129588731 | PO-269 Targeting ALDH inhibition in endometrial cancer cells |
| Q129586556 | PO-270 3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment |
| Q129588591 | PO-270 Signalling pathways WNT, hedgehog and NOTCH in breast cancer with presence and absence of cancer stem cells |
| Q129586808 | PO-271 Rise of the machines: probing intercellular crosstalk with mass spectrometry |
| Q129586077 | PO-271 Using human lung organoids to study pulmonary neuroendocrine cells |
| Q129589216 | PO-272 Leukemia-associated NPM mutations promote quiescence of hematopoietic stem cells and prevent their functional exhaustion upon oncogene-induced hyper-proliferation |
| Q129589056 | PO-272 Optimisation of hypoxia regulated timed systems for genetic ablation and tracking of hypoxic breast cancer cells to study therapy resistance |
| Q129588878 | PO-273 Aldehyde dehydrogenase 7A1 (ALDH7A1) contributes to reduction of reactive oxygen species generation in colorectal tumour microenvironment |
| Q129589096 | PO-273 Evaluation of the role of SOX2 as cancer stem cell marker in sarcomas |
| Q129589353 | PO-274 Development of an in vitro tumour model to evaluate drug efficacy and epithelial mesenchymal transition in triple negative breast cancer |
| Q129586857 | PO-274 Tumour subtype-specific cells of origin of malignant mesothelioma |
| Q129586145 | PO-275 Effect of ionising radiation in FaDu cell line- preliminary results |
| Q129589242 | PO-275 Gene expression and splicing variants changes in colorectal cancer related cell function pathways |
| Q129589227 | PO-276 Histone acetylation readers BET in hypoxia adaptation in triple negative breast cancer (TNBC) |
| Q129587585 | PO-276 Prognostic significance of LGR5, an intestinal stem cell marker, in colorectal cancers. (running head: LGR5 in colorectal cancers) |
| Q129588643 | PO-277 Postmitotic neuron-like differentiation of cancer cells suggests that cancer cells have the properties of neural precursor/progenitor cells |
| Q129587527 | PO-277 Single-cell RNA-seq analysis of human pancreatic ductal adenocarcinoma |
| Q129586519 | PO-278 Assessment of the influence of stellate cells on primary pancreatic cancer cell growth and drug resistance in a spheroid model: MET inhibitors to the rescue |
| Q129587985 | PO-278 Distinctive role of dysregulated miRNAs and mRNAs in chordoma cancer stem cells |
| Q129589456 | PO-279 Effect of the in vitro A549 neuroendocrine differentiation on the activity cytotoxic T lymphocytes |
| Q129586410 | PO-279 Interplay between Indoleamine 2,3-dioxigenase 1 and Notch1 in radiation response of cervical stem cancer cells |
| Q129588713 | PO-280 Hypoxia-induced PLD2 promotes tumorigenesis and stem cell-like properties in tumour cells |
| Q129586789 | PO-280 Mutant KRAS mediates fibroblast-induced colorectal cancer cell invasion |
| Q114978888 | PO-281 Automated multiparametric tissue imaging platform using existing microscope hardware for the detection of spatially resolved single-cell resolution data |
| Q110698997 | PO-281 SIRT1 inhibition exhibits decreased pluripotency in glioma cancer stem cells |
| Q129588623 | PO-282 Cancer-associated fibroblast-derived lumican promotes gastric cancer progression via the integrin beta1-FAK signalling pathway |
| Q129588070 | PO-282 SMAR1 transcriptionally repress hTERT and alters the stem cell population in colorectal cancer cells |
| Q129588603 | PO-283 Characterisation of hTERT-immortalised prostate-derived stromal and epithelial cells: an authentic in vitro model for tumour microenvironment studies |
| Q129589499 | PO-283 The Akt/mTOR pathway in cancer stem/progenitor cells is a therapeutic target for glioblastoma and neuroblastoma |
| Q129587248 | PO-284 Involvement of versican, a chondroitin sulfate proteolgycan in the pathogenesis of multiple myeloma |
| Q129589414 | PO-285 Immunomodulatory effects of lactobacillus strains: emphasis on identification of probiotic candidates with anti-tumour responses |
| Q129588089 | PO-285 Role of tumour associated macrophages (TAMs) in regulation of cancer stem cell (CSCs) enrichment in breast cancer |
| Q129588470 | PO-286 Evaluating the influence of mesenchymal stromal cells derivatives on early stage of breast cancer |
| Q129588077 | PO-286 Protein kinase D3: a crucial regulator of breast cancer stem cell survival |
| Q129588746 | PO-287 A novel L1/STAT3 crosstalk drives ovarian cancer stem cell function |
| Q129588080 | PO-287 ’Annex’in A1 to the breast tumour microenvironment by aiding in macrophage polarisation |
| Q129585803 | PO-288 Replication stress response as a target for eradicating colorectal cancer stem cells |
| Q129587916 | PO-288 Stroma cells increase expression of tumor-promoting RAC1B in colorectal cancer cells |
| Q129587588 | PO-289 Identification of microenvironmental regulation and therapeutic targeting of ongenic EF-2 kinase in pancreatic cancer |
| Q129586847 | PO-290 ETV7 regulates breast cancer stem cells content and chemoresistance |
| Q129589262 | PO-290 Oncostatin M signalling mediates the crosstalk between cancer cells and tumour microenvironment and promotes breast cancer progression |
| Q129585935 | PO-291 A cell-penetrating peptide based on the connexin43-Src interacting sequence reduces glioma stem cell migration and proliferation by recruiting Src, Csk and PTEN |
| Q129587153 | PO-291 The disbalance of the basic cytokines of the immune system in patients with ovarian cancer on the background of immunotherapy |
| Q129585726 | PO-292 Breast cancer stem cell reprogramming: deciphering the impact of glucose and the contribute of tumour microenvironment |
| Q129589411 | PO-293 Tumour/stroma interactions in colorectal cancer (CRC) models: role of the tumour suppressor PTEN |
| Q129586119 | PO-293 Withaferin-A: a candidate anti-tumour natural compound for non-small cell lung cancer and stem cells |
| Q129588834 | PO-294 Role of fatty acid amide hydrolase (FAAH) in breast development and cancer |
| Q129585867 | PO-295 Heterogeneity of the alpha5 integrin subunit expression in glioblastoma |
| Q129586751 | PO-296 Elucidating the potential role of CD109 as a biomarker for cancer stem-like cells in cervical cancer |
| Q129586098 | PO-296 Identification of novel players of tumour – macrophage crosstalk in lung cancer |
| Q129587284 | PO-297 Oncogenic activity of SOX1 in gastric cancer |
| Q129588493 | PO-297 PLEXINA4 plays a role in cancer progression and immune cell infiltration |
| Q129588593 | PO-298 MYC favours the onset of tumour initiating cells by inducing epigenetic reprogramming of mammary epithelial cells towards a stem cell-like state |
| Q129587606 | PO-298 Pegylated recombinant human hyaluronidase PH20 (PEGPH20) increases tumour uptake and efficacy of cetuximab in a human pancreatic cancer xenograft model |
| Q129589559 | PO-299 Aberrant TXNDC5 expression in colon stromal fibroblasts promotes colorectal cancer carcinogenesis |
| Q129588720 | PO-299 In vivo shRNA screening to identify quiescence-related genes required for AML growth |
| Q129586142 | PO-300 CIP2A-mediated regulation of senescence in basal-like breast cancer |
| Q129588087 | PO-300 Unveiling and exploiting cancer stem cell editing and immunogenicity for precision medicine |
| Q129587169 | PO-301 Diagnosis of glioma tumours using circulating cell-free DNA |
| Q129587899 | PO-301 Protein disulfide isomerase A4 regulates cancer development via cancer stromal cells |
| Q129586223 | PO-302 Deconvolution of the tumour microenvironment of primary human pancreatic ductal adenocarcinoma and normal pancreas reveals specific deregulated signalling nodes |
| Q129586902 | PO-302 The role of SPARCL1 in upper urinary tract cancer of Taiwan |
| Q129587154 | PO-303 Germline determinants of the somatic mutation landscape in 2642 cancer genomes |
| Q129588122 | PO-303 Modified P53 functionality in cancer-associated fibroblasts promotes cancer growth |
| Q129586514 | PO-304 Three-dimensional co-culture of colorectal cancer spheroid with cancer-associated fibroblast as a model to study immune cell modulation |
| Q129585897 | PO-305 Chromatin accessibility profiling identifies an underlying HNF4A-GATA6 regulatory module in oesophageal adenocarcinoma |
| Q129587233 | PO-305 Depletion of CPEB4 in the metastatic niche enhances metastatic growth |
| Q129589313 | PO-306 Identification of chromatin modifiers regulating temozolomide resistance in glioblastoma multiforme |
| Q129589192 | PO-306 Targeting CD70-positive cancer associated fibroblasts to tackle the immune suppressive tumour microenvironment in colorectal cancer |
| Q129587464 | PO-307 Differential secretome analysis of cancer-associated adipocytes (CAA) and mature adipocytes to identify adipocyte-driven micro-environmental regulators of breast cancer progression |
| Q129585947 | PO-307 Paradoxical decrease in H2AFX copy number yet increasing mRNA expression in human breast cancer |
| Q129587113 | PO-308 HAF inhibition in glioma cells reduces tumour growth without modifying the efficacy of chemo- and radiotherapy |
| Q129586208 | PO-308 Identification of genomic patterns predictive of upgrading in low-grade prostate cancer |
| Q129588153 | PO-309 Identification of genomic aberrations associated with lymph node metastasis in diffuse-type gastric cancer |
| Q129585773 | PO-310 Genomic features of premenopausal breast cancers in latin american women: the PRECAMA study |
| Q129588075 | PO-310 miRNAs in tumor-derived microvesicles promote angiogenesis and tumour cell growth |
| Q129588183 | PO-311 Characterisation of colorectal tumour endothelial cells |
| Q129586010 | PO-311 Multifocality complicates molecular classification of primary prostate cancer |
| Q129585973 | PO-312 Longitudinal transcriptomics reveals heterogeneous dynamics through the course of disease and therapy in breast cancer |
| Q129588199 | PO-313 Genome-wide analysis of site-specific hotspots in cancer |
| Q129587600 | PO-313 Inhibition of neddylation accelerates VEGF-activated VEGFR2-nitric oxide signalling for resulting in biphasic effects on angiogenesis and tumour growth |
| Q129588738 | PO-314 ALK inhibitor, ceritinib, abrogates activation of the novel ALK-I1171T mutation in neuroblastoma |
| Q129589509 | PO-314 Loss of host secretory leukocyte protease inhibitor reduces lung adenocarcinoma burden |
| Q129588485 | PO-315 Intertumor heterogeneity in vascularity and response to bevacizumab treatment in artificial melanoma brain metastases |
| Q129585744 | PO-315 The mutational and transcriptome landscape of infant B-cell acute lymphoblastic leukaemia: the INTERFANT treatment protocol experience |
| Q129589390 | PO-316 Genome-wide gene expression analysis of a murine model of prostate cancer cell progression: towards identification of high-potential therapeutic targets |
| Q129586580 | PO-316 Isoquercetin: a novel agent to increases VASH1 and suppress colon cancer |
| Q129589280 | PO-317 Improved performance and workflow using sanger sequencing for low-level somatic mutation detection from low amount of formalin-fixed paraffin-embedded (FFPE) DNA |
| Q129588085 | PO-318 De novolong interspersed element (LINE-1) insertions in high-grade serous ovarian carcinoma |
| Q129586597 | PO-318 Intestine-specific homeobox gene ISX integrates IL6 signaling, tryptophan catabolism, and immune suppression |
| Q129585798 | PO-319 Mutational signatures of 1,2-dichloropropane and dichloromethane identified in mouse carcinogenicity assays |
| Q129587859 | PO-319 Role of stanniocalcin-1 on macrophage differentiation and cytokine production |
| Q129589165 | PO-320 Anti-inflammatory effects of gossypol on human lymphocytic jurkat cells via regulation of MAPK signalling and cell cycle |
| Q129587187 | PO-320 Gene panel mutation screening for a better molecular stratification of colorectal cancer patients |
| Q129586840 | PO-321 Causes and consequences of WDHD1 overexpression in breast cancer |
| Q129589221 | PO-321 MicroRNA-145 and COX2 levels are regulated by nerve growth factor (NGF) in epithelial ovarian cancer |
| Q129586190 | PO-322 Investigating co-expression of the immune checkpoints heme oxygenase-1 and PD-L in breast cancer |
| Q129589199 | PO-322 Multi-region deep sequencing of colorectal carcinoma in-situ defines oncogenic transformation as a gradual and adaptive process |
| Q129586544 | PO-323 Tumour evolution in non-muscle-invasive bladder cancer |
| Q129586534 | PO-324 Detection of high-risk prostate cancer biomarkers by RNA sequencing and qPCR method |
| Q129586599 | PO-324 Interferon regulatory factor 1 (IRF1) regulates inflammatory and metabolic phenotypes in pancreatic ductal adenocarcinoma |
| Q129587451 | PO-325 Novel recurrent high-level amplifications in microsatellite stable colorectal cancer |
| Q129587568 | PO-325 Topological-proteomics of breast cancer intra-tumour heterogeneity reveals metabolic diversity within single tumours |
| Q129589233 | PO-326 Genetic stability of multiple recurrences in bladder cancer patients |
| Q129585951 | PO-326 Impact of miR-205–5 p and miR-425–5 p on Wnt and AR signalling pathways in castration resistant prostate cancertransition |
| Q129587378 | PO-327 Whole-genome CRISPR-CAS9 screening: the wellcome sanger institute cellular generation and phenotyping pipeline |
| Q129588111 | PO-328 No such thing as a perfect copy – DNA replication profoundly influences how most environmental carcinogens and epigenetic marks induce mutations |
| Q129587484 | PO-328 Stemness features of prostate cancer cells induced by carcinoma-associated fibroblasts |
| Q129588149 | PO-329 Genomic aberration in pancreatic neuroendocrine tumours (PNET) |
| Q129589238 | PO-329 Rejecting neutral tumour evolution across human cancer types |
| Q129587225 | PO-330 Investigating tissue- and age-specific microsatellite instability in mice with different levels of MLH1, a central mismatch repair protein |
| Q129588478 | PO-330 Prevention of worsening in glioma relapse |
| Q129585715 | PO-331 Understanding DCIS initiation and progression using tumouroid and mouse models |
| Q129587450 | PO-332 Genomic landscapes, neoantigen profiles and biological impact of MLH1 inactivation in cancer cells |
| Q129589407 | PO-332 Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E-inhibition in melanoma |
| Q129588530 | PO-333 Molecular heterogenity in neuroblastoma (on behalf of turkish paediatric oncology group) |
| Q129587925 | PO-333 Somatic engineering of mammary gland epithelial cells using CRISPR/Cas9 for rapid testing of breast cancer susceptibility genes in mouse models |
| Q129589287 | PO-334 Distribution of copy number alterations defines clonal populations involved in the evolutionary transition from adenoma-to-carcinoma in colorectal cancer |
| Q129587947 | PO-334 Identification of shared lineage programs across high-grade glioma subtypes by single-cell RNA-seq |
| Q123121896 | PO-335 EGFR and ALK mutation status in advanced lung adenocarcinoma: prevalence, gender and age-related peculiarities among patients in Ukraine |
| Q129585868 | PO-335 The effect of three-dimensional (3D) cell cultures on phenotype and gene expression of EMT- and CSC-associated genes in head and neck squamous cell carcinoma cell lines |
| Q129587967 | PO-336 Identification of SOX2 and SFRP2 as opposing regulators of glioblastoma heterogeneous subtypes |
| Q129588777 | PO-337 Preliminary observations: array-comparative genomic hybridization as a high-throughput approach against bladder cancer |
| Q129586296 | PO-337 Single cell mRNA sequencing reveals the presence of the gene expression signature of all major molecular subtypes in individual breast cancers |
| Q129588751 | PO-338 Recurrent glioblastoma: a complex scenario dominated by loss of MMR proteins |
| Q129587327 | PO-338 Tumour heterogeneity underlies differential cisplatin sensitivity in mouse models of SCLC |
| Q129588627 | PO-339 Implications of organ-wise extraction of cancer mutational signatures using 2577 whole genomes |
| Q129586520 | PO-339 Intratumour heterogeneity in a pancreatic cancer mouse model |
| Q129589277 | PO-340 Dysregulation of the TP53 network and PRC2 activity are independent poor prognostic factors in patients with malignant peripheral nerve sheath tumours |
| Q129587457 | PO-340 Tumour heterogeneity in patient-derived glioblastoma organoids |
| Q129585919 | PO-341 Functional role of APOBECS in upper aerodigestive tract tumours |
| Q129587561 | PO-341 The role of cancer/testis antigens from MAGE-A family and NY-ESO-1 in ductal carcinoma in situ (DCIS) |
| Q129585848 | PO-342 Establishment and molecular profile of a new cervical cancer cell line from brazilian patient biopsy |
| Q129587414 | PO-342 Integrating copy number analysis and tumour DNA methylation profiling |
| Q129588857 | PO-343 Targeted resequencing identifies novel and ultra-rare high-impact variants in breast cancer susceptibility genes in an Irish population |
| Q129587895 | PO-343 The microRNA-146b-IRAK1 signalling axis in tumour recurrence of papillary thyroid cancer |
| Q129587306 | PO-344 Osteoblastoma is characterised by recurrent rearrangements of FOS and FOSB |
| Q129589274 | PO-344 miR-302b as adjuvant therapeutic tool to improve chemotherapy efficacy in human triple negative breast cancer |
| Q129585306 | PO-345 Identification of AR-modulatory microRNAs for prostate cancer progression and therapy |
| Q129586729 | PO-345 The role of the deubiquitinase USP11 in endocrine-driven breast cancer |
| Q129588205 | PO-346 Defining microRNA mediated regulation of metabolic pathways involved in colon cancer progression (BST1-microRNA interactions) |
| Q129588855 | PO-346 The MYC antagonist MNT beyond MAX interaction |
| Q129589177 | PO-347 Analysis of global methylation status under the microenvironment in glioblastoma cells |
| Q129586760 | PO-347 sONE, a novel tumour suppressor lncRNA, with diminished expression level in young triple negative breast cancer (TNBC) patients with lymphnode metastasis and large tumour size |
| Q129586633 | PO-348 Two novel synthetic analogues of miR-1207–3 p, NB5 and NB1207, target AR-V7 and C-MYC and demonstrate in vivo therapeutic efficacy in metastatic castrate-resistant prostate cancer (mCRPC) |
| Q129587390 | PO-349 AKT3, but not AKT1 and AKT2, confers a longer survival rate to less aggressive breast cancers |
| Q129587551 | PO-349 Identification of differentially expressed lncRNAs in metformin resistant SH-SY5Y neuroblastoma cells |
| Q129585853 | PO-350 Case-case GWAS to identify germline metastasis risk variants in sporadic colorectal carcinomas |
| Q129589311 | PO-350 MiRNAs and their relation to biological pathways in left- and right-sided colorectal cancer |
| Q129589548 | PO-351 Melatonin suppresses TPA-induced oral cancer cell migration via lncRNA-LNC310-mediated PRUNE2 activation |
| Q129587596 | PO-351 Promo: an interactive tool for analysing large multi-omic cancer datasets |
| Q129587648 | PO-352 Hijacking hepatocellular carcinoma (HCC) tumour progression through restoring TP53/miR-15a/miR-16 tumour suppressor axis by a novel quercetin glycoside |
| Q129586660 | PO-352 The effects of lapatinib responsive miRNA on cell proliferation and cell invasion in HER2 +breast cancer cell line |
| Q129588171 | PO-353 Functional high-throughput screening reveals multiple tumour-suppressive microRNAs in neuroblastoma |
| Q129586092 | PO-353 TIP60-dependent acetylation of SPZ1-TWIST complex promotes epithelial–mesenchymal transition and metastasis in liver cancer |
| Q129588638 | PO-354 Disrupting the acetylation of ISX-BRD4 by p300/CBP-associated factor (PCAF) suppresses tumour metastasis |
| Q129588109 | PO-354 Star-shaped gene silencing nanoparticles– an advanced approach to treating medulloblastoma |
| Q129588765 | PO-355 Antitumor activity of HSA-miR-X in HER2 positive cells is mediated by the regulation of AKT and ERK |
| Q129588769 | PO-355 Enhancers mapping uncovers phenotypic heterogeneity and evolution in patients with luminal breast cancer |
| Q129588517 | PO-356 MicroRNA mediated regulation of morgana, a new oncosuppressor in chronic myeloid leukaemia |
| Q129586227 | PO-356 White blood cells from prostate cancer patients carry distinct chromosome conformations |
| Q129586688 | PO-357 miR-145–5 p, miR-196a-5p, miR-222–3 p and lncRNA MALAT1 as non-invasive markers in advanced laryngeal squamous cell carcinoma |
| Q129586117 | PO-358 CELf2 at the core of a prognostic alternative splicing signature in colorectal cancer |
| Q129587519 | PO-359 Macrophage polarisation and squamous cell carcinoma |
| Q129587361 | PO-359 Overexpression of histone H3K4 demethylases in clear cell renal cell carcinoma with LSD2 as plausible therapeutic target |
| Q129586529 | PO-360 Epigenetic changes in testicular cancer survivors treated with cisplatin |
| Q129588690 | PO-360 Vaccinia virus delivered by isolated limb perfusion combines with PD-1 blockade to prevent local and distant relapse in soft-tissue sarcoma |
| Q129588648 | PO-361 Modulation of cancer cell response to etoposide by M1 and M2 polarised macrophages |
| Q129588791 | PO-362 Influence of epigenetic agents on mouse teratoma development in vitro |
| Q129586896 | PO-362 Rational designing combinatorial T-cell based immunotherapy by high-dimensional profiling |
| Q129587362 | PO-363 Implication of global histone methylation (H3K4me) levels in the prognosis of clear cell renal cell carcinoma |
| Q129586313 | PO-364 Effect of exercise and immunotherapy on tumour immunogenicity and growth |
| Q129586028 | PO-364 LncRNA-P23154 promotes the invasion-metastasis potential of oral squamous cell carcinoma by regulating Glut1-mediated glycolysis |
| Q129589292 | PO-365 Dissecting the synergistic effect of chemotherapy and immunotherapy on anti-tumoral T cell functions in breast cancer |
| Q129589195 | PO-365 Isothiocyanates as potent epigenetic regulators in human malignant melanoma chemoprevention |
| Q129589203 | PO-366 Chemotherapy induces PD-L1 in esophageal squamous cell carcinoma |
| Q129586991 | PO-366 Long non-coding RNAs TINCR and DANCR in urothelial carcinoma subtypes |
| Q129587158 | PO-367 Brain microenvironment-secreted cytokines facilitate glioblastoma proliferation and invasion |
| Q129588105 | PO-367 DFNA5 methylation: a potential biomarker for breast cancer, on the basis of a large scale analysis in TCGA |
| Q129589451 | PO-368 Differential effects of immune activity on melanoma cell subtypes |
| Q129585938 | PO-368 Epigenetic regulation of glycosylation and the impact on chemoresistance in ovarian and breast cancer |
| Q129588538 | PO-369 Effects of cycling hypoxia on the communication between macrophages and endothelial cells in promoting tumour growth and metastasis |
| Q129589217 | PO-369 KDM3A/Ets1/MCAM axis in rhabdomyosarcoma and osteosarcoma |
| Q129585958 | PO-370 A co-culture assay system using engineered anti-CD3 tumour cells to assess tumour cell sensitivity to CD8 +T cell killing |
| Q129586726 | PO-370 Sustained over-expression of miR-26a induces chromosome instability and tumorigenesis by dysregulation of CHFR expression |
| Q129588159 | PO-371 ADAM28 deletion in mice induces CD8 +T cell decrease and impacts the onset of lung metastasis |
| Q129588209 | PO-371 Contribution of elevated miR-146b-5p to papillary thyroid cancer diagnosis and development |
| Q129588736 | PO-372 IL-2 and IL-15 cytokine in vitro treatments induce NKG2D, CD158a and CD158b receptor expression on T, NKT- like and NK cell lymphocyte subsets from regional lymph nodes of melanoma patients |
| Q129588536 | PO-372 Investigating the epigenetic changes underlying combination treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide |
| Q129587355 | PO-373 Dynamics of the esophageal tumour immune micro-environment after neoadjuvant chemoradiation (nCRT) |
| Q129586162 | PO-373 Methylation deregulation of miRNAs promoters in breast cancer in very young women |
| Q129589235 | PO-374 A 3D image-based quantification of organoid-immune cell interactions in the presence of immuno-modulators |
| Q129587442 | PO-374 LINC00152 long non-coding RNA promotes the proliferation of SW480 colon carcinoma cells through regulation of cell cycle and WNT signalling pathway |
| Q129587130 | PO-375 Analysis of miRNA expression in non-small cell lung cancer |
| Q129587324 | PO-375 Rational designing combinatorial T-cell based immunotherapy by high-dimensional profiling |
| Q129588090 | PO-376 SWI/SNF alterations as markers for prognosis and specific treatments in human cancer |
| Q129588674 | PO-377 Immune recognition of tumours by voluntary wheel running may be triggered by induction of Zbp1 |
| Q129586843 | PO-377 Whole transcriptome analysis reveals colorectal cancer-associated long non-coding RNAs including UCA1 already dysregulated in colorectal adenomas |
| Q129587950 | PO-378 Exercise-dependent regulation of immune cell function in a clinical cancer perspective |
| Q129588885 | PO-378 Systematic miRNA expression changes in human colorectal cancer development and in animal model |
| Q129588196 | PO-379 Novel tumour specific miRNA expressed in classical hodgkin lymphoma cell lines |
| Q129586166 | PO-380 Epigenetically regulated MAF is a new potential tumour suppressor gene in LSCC |
| Q129587861 | PO-380 Regulatory T cells encounter pro-inflammatory immune cells in human colorectal cancer |
| Q129589339 | PO-381 Response project: chromatin regulators as biomarkers and drug targets in colorectal cancer |
| Q129585752 | PO-382 Differentially methylated sites in histologically negative surgical margins of oral squamous cell carcinoma patients |
| Q129585997 | PO-382 Evaluation of the serum level of T-helper-17 in patients with benign and malignant salivary gland tumours |
| Q129587918 | PO-383 Profile of serum heat shock protein-27 level in patients with salivary gland tumour |
| Q129588486 | PO-384 Investigation of IL-33 serum levels in patients with benign and malignant salivary gland tumours |
| Q129588480 | PO-384 Manual and automated detection of DNA methylation alterations in colorectal neoplasia in circulating cell-free DNA fraction |
| Q129587965 | PO-385 DNA methylation profile of castration-resistant prostate cancer cells |
| Q129586014 | PO-386 Decoding the regulatory role and epiclonal dynamics of DNA methylation in 1482 breast tumours |
| Q129587250 | PO-387 Differential gene methylation in triple negative breast cancer and non-tumoral mammary tissue |
| Q129586875 | PO-387 Phenotypic and functional analysis of malignant mesothelioma tumor-infiltrating lymphocytes (TILs) |
| Q129586114 | PO-388 Epigenetic silencing of ZNF177 by MIR-877–3 p could be involved in cervical cancer progression |
| Q129587994 | PO-389 Epigenomic and mutation determinants of carcinogen-driven primary epithelial cell immortalization |
| Q129585790 | PO-390 A workflow for optimised isolation and analysis of tumour infiltrating immune subpopulations |
| Q129589420 | PO-390 Image-guided stereotactic molecular profiling of samples taken in- and outside conventional tumour boundaries highlight extensive infiltration of tumour cells in diffuse gliomas |
| Q129588129 | PO-391 DNA methylation as a probable cause of SPRR3 loss in esophageal cancer |
| Q129588722 | PO-391 High-throughput single-cell T-cell receptor profiling by SMART technology |
| Q129588078 | PO-392 Epigenetic changes in chondrosarcoma caused by IDH mutations as a target for novel anticancer therapy |
| Q129586185 | PO-392 Galectin-9 is required for dendritic cell function and directly contributes to DC-mediated anti-tumour immunity |
| Q129588079 | PO-393 Identification of housekeeping genes to quantitative real-time RT-PCR analysis by miRNA expression using liquid-based cervical cytologysamples |
| Q129586571 | PO-393 Notch3 and CXCR4 cross-signalling sustains acute T-cell leukaemia progression |
| Q129587971 | PO-394 DNA methylation of ADAM23 is negatively associated with haematogenous spread in breast cancer |
| Q129586754 | PO-394 Performance of a targeted T cell receptor beta immune repertoire sequencing panel in several FFPE tissue types – a tool for interrogation of the tumour microenvironment |
| Q129586631 | PO-395 Cortisol triggers immune escape of human acute myeloid leukaemia cells by inducing expression of G protein-coupled receptor latrophilin 1 which facilitates exocytosis of immune suppressor galectin-9 |
| Q129587583 | PO-395 Mechanistic investigation of epigenetic modifications induced by metabolic changes in AML |
| Q129588556 | PO-396 Soluble mediators released by human melanoma-associated fibroblasts interfere with cytotoxic T cell response |
| Q129586008 | PO-397 DNA damage tolerance is essential for the DNA damage response network and hematopoietic stem cell maintenance |
| Q129587352 | PO-398 Benchmarkingof amplicon-based next-generation sequencing panels combined with bioinformatics solutions for BRCA1 and BRCA2 alteration detection |
| Q129588755 | PO-398 Markers of immune exhaustion and immune suppression in immunoregulatory network of virus-associated cervical cancer: putative contribution in the induction of invasive tumour growth |
| Q129588180 | PO-399 Genome wide histone modification patterns at the promoter regions are distinct in low and high grade gliomas |
| Q129588636 | PO-399 Tumour CDKN2A loss predisposes to immunotherapy resistance |
| Q129587625 | PO-400 Arriba – fast and accurate gene fusion detection from RNA-seq data |
| Q129587108 | PO-400 Dual targeting of TIM3 and adenosine produces synergistic improvement in anti-tumour immunity |
| Q129586733 | PO-401 Detection of mutational patterns associated to HR deficiency from low counts of mutations |
| Q129587110 | PO-401 Tumour stem cell characteristics are negatively associated with anti-cancer immunity in diverse solid cancers |
| Q129589254 | PO-402 Establishment of human monoclonal anti tumour antibodies with high affinity to CD9 using an in vitro B cell affinity maturation platform |
| Q129586042 | PO-403 Discovery of a new potent and mutant-selective EGFR inhibitor that overcomes T790M-mediated resistance in lung cancer |
| Q129585819 | PO-403 The tumour suppressor P53 as a guardian of immune tolerance and suppression |
| Q129588095 | PO-404 Cisplatin and ruthenium(III) complexes – comparison of cellular response of treated MDA-MB231 breast cells |
| Q129587954 | PO-404 Using functional genetic screens to understand cancer immune evasion |
| Q129587415 | PO-405 Blockade of endothelial cell glycolysis to improve current immunotherapy |
| Q129589305 | PO-405 Repositioning existing drugs as novel therapeutics for high-risk paediatric leukaemia |
| Q129587335 | PO-406 Investigation of the repertoire of peptides bound to MHC class I molecules in tasmanian devil transmissible cancers for the development of a peptide vaccine |
| Q129588607 | PO-406 The olive-based oleocanthal as a dual HER2-MET inhibitor for the control of breast cancer |
| Q129586620 | PO-407 Identification of unique antigens on prostate cancer stem cells for cytotoxic T cell recognition |
| Q129589236 | PO-408 Methanol extract of holothuria scabra inhibits cell growth and induces apoptosis in T47D breast cancer cells |
| Q129588169 | PO-408 New targets for the immunotherapy of adult B-cell acute lymphocytic leukaemia |
| Q129588739 | PO-409 Highly specific targeting of human acute myeloid leukaemia (AML) cells using functionalised gold nanoparticles |
| Q129589465 | PO-409 Signal peptide of PD-1 inhibits cancer cell growth |
| Q129589515 | PO-410 Cytotoxicity and genotoxicity of new gadolinium, iron oxide, cobalt ferrite and graphene oxide nanoparticles on some tumour cell lines in vitro |
| Q129585922 | PO-410 Discovery of immunogenic neoantigens for peptide vaccination approaches in murine colorectal cancer |
| Q129585933 | PO-411 Combinatorial therapy with immune checkpoint blockade and theranostic tumor-targeted nanoparticles in eradication of tumours |
| Q129589060 | PO-412 Effectiveness and safety of anti-PD1 (Nivolumab) as second line treatment of advanced non-small cell lung cancer (NSCLC) elderly and heavy smokers patients (PTS) with unknown PD-1 status |
| Q129585884 | PO-412 Novel drug discovery approaches for cancer with the inspiration of a natural product – methyl jasmonate |
| Q129588742 | PO-413 Estimation of antitumor activity of amino derivatives of quinoxaline-2-carbonitrile 1,4-dioxide |
| Q129589326 | PO-413 Immune modulating properties of cyclophosphamide synergise with immunotherapy in preclinical models of neuroblastoma |
| Q129588221 | PO-414 Evaluation and comparison of drug loaded composite nano-emulsions’ cellular uptake in malignant melanoma cell line |
| Q129586149 | PO-414 Stage IV melanoma patients with tumoural MHC class i loss only respond to anti-PD-1 therapy in the presence of high NK cell density |
| Q129586005 | PO-415 Multivalent polymeric nanoparticles as an innovative cancer immunotherapy for colorectal cancer |
| Q129586854 | PO-415 New anti-migratory and anti-invasive effects of a fascin inhibitor on colorrectal cancer cells |
| Q129588548 | PO-416 A novel multifunctional polypeptide-based platform as an immunotherapeutic approach for melanoma |
| Q129587448 | PO-416 Cytotoxicity of Ru (II) and Ru (III) salen complexes against breast and colorectal cancer cell lines |
| Q129588586 | PO-417 Anti-tumoural effects of IL-15 and CD40 stimulation as a novel combination immunotherapy for pancreatic cancer |
| Q129586721 | PO-417 Synthesis of CU(II) complexes derived from imidazole and cytotoxic activity evaluation against breast and colorectal cancers |
| Q129585893 | PO-418 Targeting heat shock protein 70 (HSP70) in melanoma with functionalized theranostic superparamagnetic iron oxide nanoparticles |
| Q129586213 | PO-419 Poly(I:C) prepares glioblastoma cells for anti-PD-L1 therapy via lymphocyte attraction and activation in a TLR3-dependent manner |
| Q129586670 | PO-419 Use of origanum majorana oil in lung cancer therapy |
| Q129588143 | PO-420 Harnessing chitosan/Poly(Y)-glutamic acid nanoparticles for immunomodulation at the tumour microenvironment |
| Q129587453 | PO-420 Mechanisms of action of anti-proliferative lichen compound protolichesterinic acid |
| Q129587545 | PO-421 Anti-CTLA-4 and anti-PD-1 immunotherapies repress tumour progression through independent cellular mechanisms |
| Q129586015 | PO-422 Development of an ALK lymphoma-derived autophagosomal and dendritic cells vaccine |
| Q129586976 | PO-422 Disagregation in biological medium of promising theranostic agents for cancer |
| Q129586821 | PO-423 Investigation of combined immune checkpoint blockade in human malignant pleural mesothelioma |
| Q129588275 | PO-424 Discovery of a novel small molecule STING agonist as a new cancer immunotherapy |
| Q129588525 | PO-424 modulating hexokinase 2 (HK2) as a novel approach to target metabolic immuno-oncology |
| Q129587983 | PO-425 Combined administration of anti-IL6 and anti-PD-L1 antibodies prevents ketogenic failure, reduces tumour progression, and increases overall survival in an autochthonous murine pancreatic cancer model |
| Q129588775 | PO-425 The effect of bis structured schiff base material on apoptosis, cytotoxicity and DNA damage of breast cancer cell line |
| Q123349038 | PO-426 Gender disparity in lung adenocarcinoma susceptibility in experimental mice model |
| Q129586811 | PO-426 Targeting of VEGFR2-expressing cells by chimeric antigen receptor (CAR) T cells for solid tumour therapy |
| Q129585731 | PO-427 A nuclear-directed human pancreatic ribonuclease variant is cytotoxic for breast cancer cells cultured in 3D and kills cancer stem cells |
| Q129586087 | PO-427 Establishment of KRAS (G12D)/Trp53 null/Pdx1-cre (KPC) mouse homograft tumour models to facilitate preclinical efficacy evaluation of combinatory immunotherapies |
| Q129587254 | PO-428 Radiotherapy, immunocytokines and immune checkpoint inhibitors: finding the optimal combination |
| Q129586209 | PO-428 Therapeutic potential of nanoparticle encapsulated Wnt and YAP inhibitors using patient derived xenograft models for the treatment of triple negative breast cancer |
| Q129586887 | PO-429 Elastin-like recombinamers nanoparticles: an effective drug delivery system on colorectal cancer cells |
| Q129587217 | PO-429 Identification of the right immunostimulatory chemotherapeutic partner for anti-CD70 immunotherapy in non-small cell lung cancer |
| Q129589074 | PO-430 Natural killer cell-based adoptive immunotherapy is effective in the eradication of chemoresistant stem-like cells in bladder cancer |
| Q129588595 | PO-431 A novel strategy to treat advanced, late-stage tumours with real-time tumour vaccination |
| Q129585714 | PO-432 New combined nanoparticle therapy inhibits metastatic breast tumour growth with superior efficacy and lower side effect profile to docetaxel |
| Q129587244 | PO-432 Small molecules, peptides and antibodies – the comparison of PD-1/PD-L1 blocking potential in an in vitro immune checkpoint blockade assay |
| Q129586596 | PO-433 Prognostic relevance of PP1 in breast cancer |
| Q129586805 | PO-433 The modulation of redox homeostasis and induction of ferroptotic cell death in hepatocellular carcinoma as an anticancer strategy |
| Q129589152 | PO-434 AT1413 antibody derived from a cured AML patient recognisesa unique sialylated CD43 epitope shared by AML, MDS and melanoma cells |
| Q129588510 | PO-434 Patient-derived cancer explants preserve tumour architecture and heterogeneity in dynamic culture |
| Q129586159 | PO-435 Photoactivation of nanoparticles delivered by mesenchymal stem cells induces osteosarcoma cell death in in vitro 3D co-culture models |
| Q129585928 | PO-435 Proteomic classification of triple negative breast cancers |
| Q129588490 | PO-436 Dose-dependent relationship between metformin and the occurrence of colorectal cancer among taiwanese patients with type 2 diabetes |
| Q129587445 | PO-436 Retargeting T-cell cytotoxicity to a unique sialylated epitope on CD43 expressed by acute myeloid leukaemia |
| Q129586581 | PO-437 Drug and radio sensitivity profile of a primary CTC cell line derived from a patient with metastatic neuroendocrine tumour of the distal oesophagus |
| Q129588012 | PO-437 Ultrasound-triggered delivery of halogenated pyruvate analogues to breast cancer cells |
| Q114978886 | PO-438 Hyperthermia as neoadjuvant treatment for pancreatic tumours in murine models |
| Q129587267 | PO-438 Internalisation of cell-penetrating peptides based on CONNEXIN43 in glioma stem cells and neural cells |
| Q129585992 | PO-439 Enhanced cytotoxic and chemosensitizing effects of conjugated small gold nanoparticles |
| Q129588682 | PO-439 Establishment and characterisation of prostate cancer patient-derived organoids and cells |
| Q129589116 | PO-440 Development and characterisation of pre-clinical in vitro/in vivo models from disseminated tumour cells of melanoma patients |
| Q129587148 | PO-440 Targeting of triple negative breast tumours using liposomes as drug delivery systems for siRNA and HSP90 inhibitor |
| Q129586151 | PO-441 Characterisation of 3D patient-derived xenograft tumour microtissues for in vitro oncology drug development |
| Q129588147 | PO-441 Investigation of YAP biological relevance in medulloblastoma SHH TP53 mutated |
| Q129589077 | PO-442 Ex vivo prostate cancer culture system recapitulates in vivo response to androgen antagonist |
| Q129589412 | PO-442 In vitro assessment of sonic hedgehog (SHH) pathway inhibitior, LDE225, in paediatric ependymoma rela subgroup shows antiproliferative and proapoptotic effects |
| Q129589231 | PO-443 In vitro clinical trial for pancreatic cancer patients |
| Q129588758 | PO-444 Evaluation of novel nucleoside analogues for lung cancer treatment: an approach based on metronomic chemotherapy |
| Q129586516 | PO-444 The emerging role of junctional adhesion molecule-A (JAM-A) as a novel drug target in ductal carcinoma in situ (DCIS) |
| Q129585971 | PO-445 E7107 treatment results in aberrantly spliced transcripts and protein products of P53 pathway genes |
| Q110615771 | PO-445 The phenotypic plasticity of castration-resistant prostate cancer: from challenge to opportunity |
| Q129586610 | PO-446 Anti-tumour efficiency of 20A, a novel G-quadruplex ligand, in in vitro and in vivocancer models: ATM and autophagy interplay |
| Q129589297 | PO-446 Targeting co-regulators of hormone-receptors as a novel therapeutic approach for prostate and breast cancer |
| Q129588612 | PO-447 CDK5 as a prognostic and predictive factor in colorectal cancer patients |
| Q129587553 | PO-448 The AP-1 trancriptional complex regulates AXL-induced resistance to PI3K pathway inhibition in head and neck and esophageal cancer |
| Q129587569 | PO-449 Optimisation of an AlphaLISA assay for the characterisation of PROTAC-induced ternary complexes within cell lysates |
| Q129588195 | PO-450 Interplay between coding and non-coding genome in human parathyroid tumours |
| Q129588768 | PO-450 MEK inhibition synergizes with MDM2 inhibitors through DUSP6 suppression |
| Q129588687 | PO-451 Novel combination of tanshinone I and dexamethasone induces apoptosis in myeloma cells by modulating ERK/p38/JNK/NF-kB signalling pathway |
| Q129586569 | PO-451 Targeted proteomics to improve therapy stratification of cancer patients |
| Q129586224 | PO-452 Selective CD47 immune checkpoint blockade on tumour cells with bispecific antibodies to effectively control tumour growth: primary role of the phagocytes |
| Q129586542 | PO-453 Effect of GLP-1 on proliferation and migration in pheochromocytoma and colorectal cancer cells |
| Q129587530 | PO-454 Biological activities of novel brassinosteroid analogues in breast cancer cells |
| Q129588168 | PO-455 Epigenetic insights: resminostat regulates targets associated with the pathogenesis of cutaneous T cell lymphoma (CTCL) |
| Q129586771 | PO-456 Cell line panel profiling of all clinically approved kinase inhibitors for cancer treatment |
| Q129587384 | PO-456 Prognostic significance of protein and gene expression of C-MYC, BCL-2, BCL-6 in diffuse large B-cell lymphoma determined by digital image analysis |
| Q129585561 | PO-457 Is 8-azaguanine selectively active against aneuploid acute myeloid leukaemia? |
| Q129588669 | PO-457 Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers |
| Q129586141 | PO-458 A multicenter study to assess EGFR mutational status in plasma: focus on an optimisedworkflow for liquid biopsy in a clinical setting |
| Q129587963 | PO-458 The role of functional groups in the antitumor properties of antrafuran |
| Q129587941 | PO-459 Systemic anti-inflammatory effect of a new anticancer cyclic peptide ALOS4 |
| Q129588727 | PO-459 Unravelling endoglin as a potential therapeutic target for the treatment of uveal melanoma |
| Q129589312 | PO-460 Gene expression-based probabilistic graphical models identify three independent biological layers in colorrectal cancer |
| Q129586254 | PO-460 Targeting endoplasmic reticulum stress using thiosemicarbazones to suppress cancer progression |
| Q129588467 | PO-461 A transcriptomic and molecular approach to uncovering achaete-scute complex homolog 2 (ASCL2) as a potential novel driver gene in breast cancer |
| Q129586228 | PO-461 Mitochondria-mediated anticancer effect of diphenyleneiodonium chloride (DPI) in aggressive neuroblastoma is regulated by MYCN |
| Q129589331 | PO-462 Functional ex vivo assay reveals homologous recombination deficiency in breast cancer beyond BRCA gene defects |
| Q129586164 | PO-462 Investigating the potential anti-cancer properties of a novel src family kinase inhibitor in triple negative breast cancer |
| Q129588652 | PO-463 Augmentation of NAD+BY NQO1 activation attenuates cisplatin-mediated hearing impairment |
| Q129587555 | PO-463 Multiparametric analysis of lung cancer tissue sections using imaging mass cytometry |
| Q129589408 | PO-464 Endoglin-targeted therapy demonstrates strong preclinical anti-tumour activity in ewing sarcoma using antibody-drug conjugates |
| Q129587281 | PO-464 Influence of natural DNA-binding compounds with cancer preventive activity on chromatin structure |
| Q129588606 | PO-465 Effect of pain management drugs in metastatic prostate cancer: in vitro studies |
| Q129586783 | PO-465 N-glycans of pseudomyxoma peritonei present highly increased fucosylation and multifucosylation correlates with high-grade morphology |
| Q129586624 | PO-466 PI3K-C2A regulates mitotic spindle assembly and chemotherapy response in breast cancer |
| Q129586000 | PO-467 Integrative modelling to understand and predict cancer drug response |
| Q129587559 | PO-467 Unclarified cases of microsatellite instability analyses for lynch syndrome diagnostics |
| Q129585889 | PO-469 Role of promoter hypermethylation of hocT1 gene (SLC22A1) in response to imatinib of chronic myeloid leukaemia patients |
| Q129588198 | PO-470 hOCT1 gene polymorphism M420del is associated with decreased response to imatinib in CML patients and amp; its effect is counteracted by M408V polymorphism |
| Q129586639 | PO-471 Circular RNA detection in melanoma patients’ plasma |
| Q129587391 | PO-471 Exosomes and transferring of hormonal resistance of breast cancer cells |
| Q129585828 | PO-472 Chemotherapy resistance-associated epithelial to endothelial transition in gastric cancer |
| Q129586644 | PO-472 MicroRNA as biomarkers of resistance to regorafenib in metastatic colorectal cancer patient |
| Q129588710 | PO-473 Quantification of ERCC1-XPF complexes in ovarian cancer xenografts with different sensitivity to cisplatin |
| Q129589386 | PO-473 WNT6 expression in glioblastoma: mechanistic, functional and clinical implications |
| Q129586844 | PO-475 Unravelling the role of sialylation in targeted therapy resistance using 3D cancer models |
| Q129587263 | PO-476 Correlation between circulating tumour DNA and progression-free survival and tumour burden in initial diagnosis of advanced-stage non-small cell lung cancer |
| Q129585941 | PO-476 Increased ERK phosphorylation as a candidate driver of resistance to the experimental cancer drug AT13148 |
| Q129587308 | PO-477 A novel role for nanog as an early cancer risk marker in patients with laryngeal precancerous lesions |
| Q129589168 | PO-477 BCL-Xl inhibition enhances dinaciclib-induced cell death in soft-tissue sarcoma cell lines |
| Q129588132 | PO-478 Chemosensitization of cisplatin-resistant testicular germ cell tumours cells |
| Q129587149 | PO-478 Prognostic significance of E-cadherin and beta-catenin expression in HPV-negative oropharyngeal squamous cell carcinomas |
| Q129586274 | PO-479 Development and characterisation of everolimus resistant breast cancer cells |
| Q129588114 | PO-479 NUB1 as a prognostic marker in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis |
| Q129587623 | PO-481 Alteration in epigenetic-related genes and histones modifications levels revealed as a potential resistance factor to oxaliplatin in colorectal cancer cells |
| Q129586858 | PO-481 Patient-derived sarcoma primary cell lines with preserved cancer stem cell properties to screen anticancer compounds |
| Q129589282 | PO-482 Analysis of small RNA cargo in urinary and plasma EVs and matching prostate cancer and normal prostate tissues |
| Q129585943 | PO-482 Efficacy of inhibition of BAD Ser99 phosphorylation by a novel small molecule in cisplatin resistant ovarian cancer |
| Q129586905 | PO-483 Improved sensitivity for non-invasive diagnosis of high-grade serous ovarian cancer |
| Q129589099 | PO-483 Phenotype switching as an escape mechanism to targeted therapies in melanoma |
| Q129588829 | PO-484 Development of a two-step screening-and-confirmation approach to efficiently identify synergistic drug combinations with the PARP inhibitor niraparib |
| Q129588511 | PO-484 Immunohistochemical analysis of mTORC1 and mTORC2-related proteins in renal cell carcinoma of kidney transplant recipients |
| Q129586250 | PO-485 Ferroptosis is the nexus for zero-valent iron-based highly selective anticancer nanotherapy and anti-nanoresistance |
| Q129586575 | PO-485 Low abundance circulating proteins in giant cell tumours of bone |
| Q129588190 | PO-486 Surrogate biomarkers of clinical efficacy in stage IIIB/IV non-small-cell lung cancer patients treated with an optimised EGF-based vaccination schedule |
| Q129587364 | PO-487 Cellular glycosylation affects trastuzumab binding and sensitivity of breast cancer cells to doxorubicin and growth factors |
| Q129589153 | PO-487 Prognosis of triple negative breast cancer is associated with MHC II genes |
| Q129589085 | PO-488 AGR2 is a progression marker and a potential therapeutic target in non-muscle invasive bladder cancer |
| Q129587408 | PO-488 Activation of Wnt signalling in temozolomide (TMZ) treated glioma cells: mechanism and implications in TMZ chemoresistance |
| Q129589363 | PO-489 TP53 mutations and focal genomic amplifications for ctDNA detection in high-grade serous ovarian carcinoma |
| Q129585734 | PO-489 Tumour-specific oncogenic signalling activities define sensitivity to combinatorial MEK inhibition and stratify Kras-driven lung cancer |
| Q129587283 | PO-490 Expression of cortactin and focal adhesion kinase in early stages of laryngeal tumorigenesis and clinical application for cancer risk-stratification |
| Q129588774 | PO-491 Frequent mTORC1 activation in head and neck squamous cell carcinomas correlates with favourable clinical outcome |
| Q129587215 | PO-491 Single-cell phenotypic profiling of breast cancerpatient-derived tumour xenografts using mass cytometry |
| Q129588589 | PO-492 Establishment of new drug-resistant gastric cancer cell lines |
| Q129587144 | PO-492 Ex vivo functional homologous recombination (HR) test detects BRCA reversal and resistance to PARPi in metastatic breast cancer patients |
| Q129589232 | PO-493 Targeting the drug resistance epigenetic driver SMYD3 as a new strategy to potentiate chemotherapeutic effects |
| Q129589228 | PO-493 ctDNA profiles of metastatic melanoma patients under therapy |
| Q129589267 | PO-494 A pathogenic network of novel molecular mechanisms driving merkel cell carcinomas. shared oncogenic pathways between virus-positive and UV-induced tumours |
| Q129586537 | PO-494 Using functional genetic screens to understand resistance to PARPi in BRCA-deficient tumours |
| Q129587526 | PO-495 PI3K pathway upregulation mediates acquired resistance to platinum agents and polyadenoribose polymerase inhibitors (PARPi) in BRCA1-methylated ovarian cancer (OC) |
| Q129585964 | PO-495 Prediction of chemotherapy sensitivity on ascites of ovarian cancer patients |
| Q129587125 | PO-496 Integrated OMICS- based approach to the identification of specific expression profiles associated with PTEN-loss |
| Q129585858 | PO-496 Loss of PARG drives PARP inhibitor resistance in BRCA2-deficient mouse mammary tumours |
| Q129587440 | PO-497 Microtubule regulatory proteins as predictive biomarkers of taxane-based chemoresistance in breast cancer? |
| Q129588779 | PO-498 Quantifying the dynamics of acquired treatment resistance and evolutionary herding for the prediction of collateral sensitivity in cancer model systems |
| Q129586399 | PO-498 Spliced RNA panels from tumor-educated platelets (TEP) enable detection of early breast cancer |
| Q129585948 | PO-499 Comparison of expression of miR21’s guide strand (5P) and passenger strand (3P) in breast tumour progression |
| Q129586820 | PO-500 A novel role for junctional adhesion molecule-a (JAM-A) in HER2-positive gastro-oesophageal cancers |
| Q129585878 | PO-500 NRF2 represents a convergent point of acquired resistance in HER2 positive gastric cancer models |
| Q129588842 | PO-501 Deconstructing the role of CD44 in gastric cancer resistance to cisplatin |
| Q129586210 | PO-501 Loss of SOX9 expression is a predictive marker of relapse in gastric cancer |
| Q129588625 | PO-502 A potential role for HSP90 in HER2-driven breast cancer (BC) |
| Q129589157 | PO-503 HDAC inhibitor resistance in colorectal cancer: RAS and AMP; MYC – the partners in crime |
| Q129585851 | PO-503 The cohesin stromal antigen 1 (SA-1) modulates colonic and colorectal cancer (CRC) stem cells: mechanism for racial disparities |
| Q129589308 | PO-504 EXPEL: a novel non-destructive method for mining soluble tumour biomarkers |
| Q129586003 | PO-504 The impact of KRAS mutations on the cytotoxic effects of afatinib and allitinib in non-small cell lung cancer cell line |
| Q129588752 | PO-505 Prognostic impact of KRAS splicing in microsatellite stable colorectal cancer |
| Q129588496 | PO-505 Targeting PIM kinase to overcome resistance to PI3K-mTOR inhibition in NSCLC |
| Q129587587 | PO-506 Targeting membrane-bound Hsp70 on cancer cells with functionalized superparamagnetic nanoparticles: new perspectives for early diagnosis and therapy |
| Q129587374 | PO-506 The dynamics of HER2 status in esophageal adenocarcinoma |
| Q129586564 | PO-507 ADAM22 as a therapeutic target for endocrine resistant metastatic breast cancer |
| Q129587536 | PO-507 Deregulated mechanisms downstream of PLCG1 promoting cutaneous T cell lymphomaprogression |
| Q129588543 | PO-508 A novel predictor for stratifying pancreatic cancer patients to DNA damage checkpoint inhibitors |
| Q129588554 | PO-508 Detection and role of novel fusion oncogenes in paediatric cancers |
| Q129588681 | PO-509 CD44V6 is a marker of poor prognosis and has potential as predictive marker of response to conventional chemotherapy in gastric cancer |
| Q129586846 | PO-509 Novel molecular classification of muscle-invasive bladder cancer opens new treatment opportunities |
| Q129585237 | PO-510 Investigation of potential therapeutic targets by using in silico methods in glioblastoma |
| Q129585974 | PO-510 XRCC6BP1: a novel role in the DNA repair of platinum resistant NSCLC cells |
| Q129586598 | PO-511 High miR-9 levels represent a novel prognostic biomarker to predict development of malignant meningioma |
| Q129585904 | PO-511 Somatic and germline calls from tumour/normal whole genome data: bioinformatics workflow for reproducible research |
| Q129586090 | PO-512 Gene expression signature comprising distinct stromal and tumor-intrinsic signals predicts response to combined anti-PD1 and anti-CTLA4 checkpoint inhibition |
| Q129589160 | PO-512 Protein markers of progression risk in patients with squamous cell vulvar carcinoma |
| Q129587493 | PO-513 Using MAPK and PI3K signalling to predict patient outcome in resectable stage IIIB/C melanoma patients neoadjuvantly treated with dafrafenib and trameitinib |
| Q129587490 | PO-514 Can ketamine be an optimal anaesthetic drug for cancer resection? a randomisedcontrolled clinical trial |
| Q129587575 | PO-514 High-throughput drug screening to identify therapies reversing aberrant cell differentiation in AML |
| Q129585817 | PO-515 Transcriptome analysis identified alcam expression as potential biomarker to LSCC patient’s outcome |
| Q129588838 | PO-516 E6/E7 RNA(LIP): a novel liposomal RNA vaccine for treatment of patients with HPV16-positive malignancies |
| Q129589328 | PO-516 Genes of infiltrated immune cells are prognosis biomarkers in specific subtypes of colorectal cancer |
| Q129587949 | PO-517 Peptide-based diagnostic in vivo targeting of membrane Hsp70 positive tumours |
| Q129586532 | PO-517 Protein profiling in colorectal cancer: from biological mapping to functional validation |
| Q129585725 | PO-518 Biomarker signature defines a potential therapeutic subclass of triple negative breast cancer |
| Q129587107 | PO-518 Localization of prostate cancer metastases– diagnostic value of quantitative PET parameters |
| Q129587117 | PO-519 Can PSA level and its change in time predict localization of proastate cancer relapse, assesed by PET-CT with 18F-Choline? |
| Q129587203 | PO-519 Combined inhibition of MEK and PI3KCA pathway induces synergic antitumor activity in HER2 amplified colorectal cancer models |
| Q129588516 | PO-520 Comprehensive molecular classification of localised prostate adenocarcinoma reveals a tumour subtype predictive of a non-aggressive disease |
| Q129586155 | PO-520 POLE gene mutation analysis in colorectal cancer patients with MSS – a pilot study |
| Q129587220 | PO-521 Expression of oestrogen receptor beta as a predictive marker of platinum and taxane-based chemotherapy in ovarian cancer patients |
| Q129587265 | PO-521 Gene expression-based subtypes of pancreatic ductal adenocarcinoma offer leads for targeted therapy |
| Q129588675 | PO-522 Biological layers identified two independent classifications in melanoma tumours |
| Q129585856 | PO-522 Global proteome and phosphoprotein profiling of meningiomas reveals novel potential therapeutic targets and biomarkers |
| Q129588010 | PO-523 Sensitivity of colorectal cancer (CRC) CRIS subtypes to SMAC mimetic birinapant with standard of care chemotherapeutics: implications for personalised medicine |
| Q129586640 | PO-523 Unveiling the microRNA signature of gastric cancer exosomes: longitudinal and cross-sectional perspectives |
| Q129588154 | PO-524 MT4-MMP, EGFR and Rb expressions are predictive biomarkers of response to erlotinib-palbociclib combination in TNBC |
| Q129588016 | PO-525 Molecular signatures of circulating microRNAs as early breast cancer biomarkers |
| Q98621905 | Pain workshop ESMO: Africa (response) |
| Q55210233 | Palliative treatment with radiation-emitting metallic stents in unresectable Bismuth type III or IV hilar cholangiocarcinoma. |
| Q128572435 | Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer |
| Q93267193 | Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel |
| Q90861362 | Patient-reported outcomes in a phase II study of alectinib |
| Q55710220 | Patient-reported outcomes in a phase II, North American study of alectinib in patients with ALK-positive, crizotinib-resistant, non-small cell lung cancer. |
| Q55504137 | Patient-reported pain severity, pain interference and health status in HR+/HER2- advanced/metastatic breast cancer. |
| Q55287059 | Patient-reported tolerability of adverse events in phase 1 trials. |
| Q113874541 | Patterns of care and outcomes of 417 patients with METAstatic SYNovial sarcoma (METASYN): real-life data from the French Sarcoma Group (FSG) |
| Q55142588 | Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain-a model-based analysis. |
| Q55117001 | Pemetrexed-cisplatin with concurrent thoracic radiation after pemetrexed-cisplatin induction in patients with unresectable locally advanced non-squamous NSCLC: results by age subgroup. |
| Q54956905 | Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab. |
| Q100315741 | Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial |
| Q64062066 | Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases |
| Q90299705 | Phase I study of TrasGEX, a glyco-optimised anti-HER2 monoclonal antibody, in patients with HER2-positive solid tumours |
| Q55005321 | Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI). |
| Q128681931 | Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors |
| Q55111944 | Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours. |
| Q55224235 | Phase I study of tomuzotuximab, a glycoengineered therapeutic antibody against the epidermal growth factor receptor, in patients with advanced carcinomas. |
| Q90861343 | Phase I, open-label study of pasireotide in patients with BRAF-wild type and NRAS-wild type, unresectable and/or metastatic melanoma |
| Q97528413 | Phase I, open-label, multicentre study of buparlisib in combination with temozolomide or with concomitant radiation therapy and temozolomide in patients with newly diagnosed glioblastoma |
| Q103825789 | Phase I/IIa, open-label, multicentre study to evaluate the optimal dosing and safety of ODM-203 in patients with advanced or metastatic solid tumours |
| Q90861349 | Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer) |
| Q104745965 | Phase II study of eribulin in combination with gemcitabine for the treatment of patients with locally advanced or metastatic triple negative breast cancer (ERIGE trial). Clinical and pharmacogenetic results on behalf of the Gruppo Oncologico Italian |
| Q54162899 | Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. |
| Q98575130 | Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503) |
| Q101241759 | Phase II trial of ribociclib and letrozole in patients with relapsed oestrogen receptor-positive ovarian or endometrial cancers |
| Q54990179 | Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. |
| Q55264112 | Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. |
| Q129588555 | Po-212 CEP55 over-expression causes genomic instability to initiate spontaneous tumour formation in vivo |
| Q129586630 | Po-309 Characterisation of the immune microenvironment of colorectal cancer using a novel high-plex protein analysis technology |
| Q129586861 | Po-323 In vivo monitoring of tumour responses to chemotherapy using multiparameter fluorescence imaging |
| Q129585794 | Po-327 Modelling intratumor heterogeneity through CRISPR-barcodes |
| Q98646963 | Positive tumour CD47 expression is an independent prognostic factor for recurrence in resected non-small cell lung cancer |
| Q90299673 | Postoperative chemotherapy with single-agent fluoropyrimidines after resection of colorectal cancer liver metastases: a meta-analysis of randomised trials |
| Q55715397 | Potential new biomarkers for squamous carcinoma of the uterine cervix. |
| Q55249373 | Practical issues of biomarker-assisted targeted therapy in precision medicine and immuno-oncology era. |
| Q117042566 | Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy |
| Q90050880 | Precision oncology in urothelial cancer |
| Q58698377 | Precision oncology: separating the wheat from the chaff |
| Q102219893 | Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer |
| Q28067482 | Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma |
| Q64998084 | Predictive value of improvement in the immune tumour microenvironment in patients with breast cancer treated with neoadjuvant chemotherapy. |
| Q92091033 | Preferences to receive unsolicited findings of germline genome sequencing in a large population of patients with cancer |
| Q58762727 | Preparing for the incoming wave of biosimilars in oncology |
| Q96639488 | Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform |
| Q129437483 | Prevalence and factors associated with professional burnout in Polish oncologists—results of a nationwide survey |
| Q102210210 | Prevalence and prognostic impact of comorbidities and peripheral blood indices in sarcomas |
| Q55229726 | Prevalence of hypothyroidism among patients with breast cancer treated with radiation to the supraclavicular field: a single-centre survey. |
| Q102335573 | Prevention of venous thromboembolism in ambulatory patients with cancer |
| Q91673681 | Prognosis of early stage small cell bladder cancer is not always dismal |
| Q58694195 | Prognostic Nutritional Index as an independent prognostic factor in locoregionally advanced squamous cell head and neck cancer |
| Q58698384 | Prognostic Nutritional Index: an easy nutritional screening for patients with head and neck cancer? |
| Q100453954 | Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases |
| Q94947942 | Prognostic impact of indoleamine 2,3-dioxygenase 1 (IDO1) mRNA expression on circulating tumour cells of patients with head and neck squamous cell carcinoma |
| Q64997225 | Prognostic implications of mismatch repair deficiency in patients with nonmetastatic colorectal and endometrial cancer. |
| Q55267388 | Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. |
| Q104745954 | Prognostic model for risk stratification of de novo metastatic nasopharyngeal carcinoma patients treated with chemotherapy followed by locoregional radiotherapy |
| Q91610309 | Prognostic nomogram based on the metastatic lymph node ratio for gastric neuroendocrine tumour: SEER database analysis |
| Q101381663 | Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial |
| Q112646265 | Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer |
| Q64990242 | Prospective analysis of 895 patients on a UK Genomics Review Board. |
| Q89553736 | Proxies of quality of life in metastatic colorectal cancer: analyses in the RECOURSE trial |
| Q55319545 | QTWiST analysis of the RECOURSE trial of trifluridine/tipiracil in metastatic colorectal cancer. |
| Q54889286 | Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma: results from a randomised controlled trial. |
| Q54947491 | Quality to rely on: meeting report of the 5th Meeting of External Quality Assessment, Naples 2016. |
| Q90299720 | Questions asked in the everyday practice: immune checkpoint inhibitors |
| Q91968493 | Radiation therapy during the coronavirus disease 2019 (covid-19) pandemic in Italy: a view of the nation's young oncologists |
| Q54002435 | Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III trial (RadioCORRECT study). |
| Q28079904 | Radiological staging in pregnant patients with cancer |
| Q98574898 | Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: patient-reported outcomes across two randomised clinical trials |
| Q91673708 | Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer |
| Q89807855 | Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study |
| Q58773448 | Rationale and design of the TRUSTY study: a randomised, multicentre, open-label phase II/III study of trifluridine/tipiracil plus bevacizumab versus irinotecan, fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic co |
| Q125634553 | Rationale and study design of the CHIPPI-1808 trial: a phase III randomized clinical trial evaluating hyperthermic intraperitoneal chemotherapy (HIPEC) for stage III ovarian cancer patients treated with primary or interval cytoreductive surgery |
| Q90711337 | Rationale of the rare cancer list: a consensus paper from the Joint Action on Rare Cancers (JARC) of the European Union (EU) |
| Q112708465 | Real-world circulating tumor DNA analysis depicts resistance mechanism and clonal evolution in ALK inhibitor-treated lung adenocarcinoma patients |
| Q98574871 | Real-world clinical outcome and toxicity data and economic aspects in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy: the experience of the Hellenic Cooperative Oncol |
| Q101225154 | Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients |
| Q117042572 | Real-world data in oncology: a questionnaire-based analysis of the academic research landscape examining the policies and experiences of the cancer cooperative groups |
| Q64966446 | Real-world features associated with cancer-related venous thromboembolic events. |
| Q55425909 | Recent advances in adjuvant therapy for patients with melanoma. |
| Q54962187 | Recent advances in the biology and treatment of brain metastases of non-small cell lung cancer: summary of a multidisciplinary roundtable discussion. |
| Q28070120 | Recent advances in the biology of human circulating tumour cells and metastasis |
| Q28072755 | Recent developments and translational aspects in targeted therapy for metastatic breast cancer |
| Q97528401 | Rechallenge of denosumab in jaw osteonecrosis of patients with unresectable giant cell tumour of bone: a case series analysis and literature review |
| Q112825265 | Recommendations for a practical implementation of circulating tumor DNA mutation testing in metastatic non-small-cell lung cancer |
| Q94947943 | Recurrent squamous cell carcinoma of the perianal skin: a case report |
| Q54998380 | Reduction in nephrotoxicities using short hydration for chemotherapy containing cisplatin: a consecutive analysis of 467 patients with thoracic malignancies. |
| Q55380623 | Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie. |
| Q28079168 | Renal insufficiency and cancer treatments |
| Q54963659 | Reply to 'Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers'. |
| Q94684161 | Reply to Authors |
| Q54001082 | Reply to Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. |
| Q59133674 | Report from the ESMO 2018 presidential symposium-Radiotherapy to the primary tumour for men with newly diagnosed metastatic prostate cancer: survival results from STAMPEDE |
| Q57071162 | Report on the status of women occupying leadership roles in oncology |
| Q98196262 | Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma |
| Q55316420 | Response: Concerns with conclusions in the article by Sherwood et al 'Key differences between 13 KRAS mutation detection technologies and their relevance for clinical practice'. |
| Q55182736 | Response: Effects of physical activity on depressive symptoms during breast cancer survivorship: a meta-analysis of randomised control trials. |
| Q100958293 | Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies |
| Q54097440 | Results of the safety run-in part of the METAL (METformin in Advanced Lung cancer) study: a multicentre, open-label phase I-II study of metformin with erlotinib in second-line therapy of patients with stage IV non-small-cell lung cancer. |
| Q54977835 | Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer. |
| Q99571851 | Retrospective analysis of the prevalence of specialised palliative care services for patients with metastatic breast cancer |
| Q55002911 | Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. |
| Q28076777 | Review of hormone-based treatments in postmenopausal patients with advanced breast cancer focusing on aromatase inhibitors and fulvestrant |
| Q55118995 | Ribociclib: a valuable addition to treatment options in breast cancer? |
| Q58694213 | Risk factors for the development of brain metastases in patients with HER2-positive breast cancer |
| Q55233903 | Rituximab biosimilars open new horizons in immunotherapy. |
| Q55399016 | Role of chemotherapy in resectable liver metastases from colorectal cancer: food for thought from pooled evidence. |
| Q55318920 | S-1 and oxaliplatin (SOX) plus bevacizumab versus mFOLFOX6 plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer: updated overall survival analyses of the open-label, non-inferiority, randomised phase III: SOFT stud |
| Q98906099 | SARS-CoV-2 seroprevalence in oncology healthcare professionals and patients with cancer at a tertiary care centre during the COVID-19 pandemic |
| Q129588822 | SPOT-001 Molecular and biophysical determinants of chromosomal translocations: a multiomics approach |
| Q129589404 | SPOT-002 Caspase-3 regulates YAP-dependent organ size and tumour development |
| Q129588155 | SPOT-003 Thymidylate synthase maintains the undifferentiated state of aggressive breast cancers |
| Q129588104 | SPOT-004 NEDD9 is crucial for tumour progression in renal cell carcinoma mouse models |
| Q129587991 | SPOT-006 Stem cell-associated heterogeneity in glioblastoma is a result of intrinsic tumour plasticity shaped by the microenvironment |
| Q129587160 | SPOT-007 Identifying novel combinatorial synthetic lethal vulnerabilities in KRAS-driven lung cancer |
| Q129589268 | SPOT-008 Neurotensin receptor type 2 protects B-cell chronic lymphocytic leukaemia cells from apoptosis |
| Q129589237 | SPOT-009 Identification of novel hippo pathway regulators using a genome wide CRISPR screen |
| Q129587103 | SPOT-011 Studying the implication of the RAS/MAPK and PI3K/AKT/TOR pathways in prostate cancer through an in vivo model of drosophila accessory glands tumorigenesis |
| Q129586752 | SPOT-012 Large-scale CRISPR screening to identify actionable cancer drug targets |
| Q92091040 | STK11 and KEAP1 mutations as prognostic biomarkers in an observational real-world lung adenocarcinoma cohort |
| Q55283312 | Safeguarding the future of independent, academic clinical cancer research in Europe for the benefit of patients. |
| Q55065627 | Safety and activity of IT-139, a ruthenium-based compound, in patients with advanced solid tumours: a first-in-human, open-label, dose-escalation phase I study with expansion cohort. |
| Q55266511 | Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma. |
| Q92684900 | Safety and efficacy of naldemedine in cancer patients with opioid-induced constipation: a pooled, subgroup analysis of two randomised controlled studies |
| Q55025685 | Safety and immunogenicity of MAGE-A3 cancer immunotherapeutic with dacarbazine in patients with MAGE-A3-positive metastatic cutaneous melanoma: an open phase I/II study with a first assessment of a predictive gene signature. |
| Q54945635 | Safety and immunogenicity of the PRAME cancer immunotherapeutic in metastatic melanoma: results of a phase I dose escalation study. |
| Q55073748 | Safety data from the phase III Japanese ACHIEVE trial: part of an international, prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer. |
| Q96124448 | Safety, efficacy and patient-reported outcomes with trifluridine/tipiracil in pretreated metastatic colorectal cancer: results of the PRECONNECT study |
| Q90437259 | Safety, tolerability and clinical implementation of 'ready-to-use' 68gallium-DOTA0-Tyr3-octreotide (68Ga-DOTATOC) (SomaKIT TOC) for injection in patients diagnosed with gastroenteropancreatic neuroendocrine tumours (GEP-NETs) |
| Q54918484 | Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors. |
| Q64065064 | Screening tool for malignant bowel obstruction in relapsed, metastatic ovarian cancer |
| Q98732999 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial |
| Q54970742 | Second-line treatments: moving towards an opportunity to improve survival in advanced gastric cancer? |
| Q55088555 | Sequential HER2 blockade as effective therapy in chemorefractory, HER2 gene-amplified, RAS wild-type, metastatic colorectal cancer: learning from a clinical case. |
| Q112289900 | Serologic response to COVID-19 infection and/or vaccine in cancer patients on active treatment |
| Q55110249 | Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. |
| Q113874537 | Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry |
| Q122947065 | Sex and gender perspectives in colorectal cancer |
| Q104745951 | Sex as decisive variable in lymphoid neoplasms-an update |
| Q99616288 | Sex differences in cancer chemotherapy effects, and why we need to reconsider BSA-based dosing of chemotherapy |
| Q102053470 | Sex-specific and gender-specific aspects in patient-reported outcomes |
| Q102378117 | Sex-specific aspects of epidemiology, molecular genetics and outcome: primary brain tumours |
| Q55262824 | Shortening adjuvant chemotherapy in stage III colon cancer: are we ready for a change? |
| Q55153362 | Single institution long-term efficacy and safety analysis of abiraterone acetate (AA) in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) in a named patient programme (NPP). |
| Q55309832 | Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis. |
| Q91785334 | Single-institute comparison of the efficacy of systemic chemotherapy for oesophagogastric junction adenocarcinoma and stomach adenocarscinoma in a metastatic setting |
| Q102053464 | Soluble PD-L1 is associated with local and systemic inflammation markers in primary and secondary brain tumours |
| Q58762789 | Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme |
| Q54969586 | Specific CDK4/6 inhibition in breast cancer: a systematic review of current clinical evidence. |
| Q91047160 | Stereotactic body radiation therapy in combination with systemic therapy for metastatic renal cell carcinoma: a prospective multicentre study |
| Q54989107 | Successful osimertinib treatment for leptomeningeal carcinomatosis from lung adenocarcinoma with the T790M mutation of EGFR. |
| Q97528427 | Supplemental parenteral nutrition: decisions based on weak evidence |
| Q54937562 | Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do? |
| Q54866500 | Survey of the management of chemotherapy-induced peripheral neuropathy in Japan: Japanese Society of Medical Oncology. |
| Q129445979 | Survival impact of post-operative immunotherapy in resected stage III cutaneous melanomas in the checkpoint era |
| Q92684921 | Survival of patients with metastatic HER2 positive gastro-oesophageal cancer treated with second-line chemotherapy plus trastuzumab or ramucirumab after progression on front-line chemotherapy plus trastuzumab |
| Q92684874 | Susceptible loci associated with autoimmune disease as potential biomarkers for checkpoint inhibitor-induced immune-related adverse events |
| Q55514098 | Switching from standard to dose-dense chemotherapy in front-line treatment of advanced ovarian cancer: a retrospective study of feasibility and efficacy. |
| Q97535476 | Systemic chemotherapy for gastro-oesophagogastric junction adenocarcinoma and stomach adenocarcinoma in a metastatic setting |
| Q55389129 | TAS-102 and the quest for predictive biomarkers. |
| Q54162903 | TKI-induced pure red cell aplasia: first case report of pure red cell aplasia with both imatinib and nilotinib. |
| Q55644910 | TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma. |
| Q56368555 | TRIPLETE: a randomised phase III study of modified FOLFOXIRI plus panitumumab versus mFOLFOX6 plus panitumumab as initial therapy for patients with unresectable and wild-type metastatic colorectal cancer |
| Q64284091 | Targeted therapy in cervical cancer |
| Q55182988 | Targeting immune checkpoints in breast cancer: an update of early results. |
| Q92684929 | Targeting prognostic proinflammatory biomarkers to improve outcome on IO drugs |
| Q54305229 | Teleconsultation ultrasonography: a new weapon to combat cholangiocarcinoma. |
| Q100761051 | Tetracyclines increase the survival of NSCLC patients treated with EGFR TKIs: a retrospective nationwide registry study |
| Q94410807 | Thank you to our reviewers 2016 |
| Q55344317 | The 'Charter of Rights for Family Caregivers'. The role and importance of the caregiver: an Italian proposal. |
| Q113442439 | The COVID-19 pandemic could be a setback for gender equality in oncology—and a key moment to push ahead with transformative policies |
| Q100385689 | The DNA damage repair (DDR) pathway in biliary tract cancer (BTC): a new Pandora's box? |
| Q55175552 | The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information. |
| Q54738129 | The ESMO/ASCO Global Curriculum and the evolution of medical oncology training in Europe. |
| Q55412581 | The European Cancer Patient's Bill of Rights, update and implementation 2016. |
| Q104745957 | The European Medicines Agency review of the initial application of atezolizumab and the role of PD-L1 expression as biomarker for checkpoint inhibitors |
| Q55181578 | The European Society for Medical Oncology 'Magnitude of Clinical Benefit Scale' field-tested in infrequent tumour entities: an extended analysis of its feasibility at the Medical University of Vienna. |
| Q55017077 | The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. |
| Q55029610 | The care of adolescents and young adults with cancer: results of the ESMO/SIOPE survey. |
| Q96639279 | The clinical and cost-effectiveness of supplemental parenteral nutrition in oncology |
| Q128460728 | The combination treatment of oncolytic adenovirus H101 with nivolumab for refractory advanced hepatocellular carcinoma: an open-label, single-arm, pilot study |
| Q92972140 | The earlier the better? Apalutamide for non-metastatic castration resistant prostate cancer |
| Q55058089 | The effect of adjuvant chemotherapy in male breast cancer: 134 cases from a retrospective study. |
| Q55397977 | The hard road to ranking the clinical benefit of antineoplastic agents: ESMO Award 2016 presentation. |
| Q104745959 | The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center |
| Q129660451 | The increasing burden of testicular seminomas and non-seminomas in adolescents and young adults (AYAs): incidence, treatment, disease-specific survival and mortality trends in the Netherlands between 1989 and 2019 |
| Q89494899 | The integrating nutritional therapy in oncology (INTO) project: rationale, structure and preliminary results |
| Q54980315 | The promise of immunotherapy in head and neck squamous cell carcinoma: combinatorial immunotherapy approaches. |
| Q96223278 | The rationale behind targeting the ICOS-ICOS ligand costimulatory pathway in cancer immunotherapy |
| Q64102014 | The role of hormone therapy and chemotherapy in oligometastatic prostate cancer |
| Q89807845 | The sarcoma diagnostic interval: a systematic review on length, contributing factors and patient outcomes |
| Q28071772 | Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence |
| Q100533130 | Thirteen-year analyses of medical oncology outpatient day clinic data: a changing field |
| Q29303933 | Threat posed by unproven drugs in medical oncology |
| Q54990183 | Time since start of first-line therapy as a predictive clinical marker for nintedanib in patients with previously treated non-small cell lung cancer. |
| Q57298272 | Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature |
| Q96431072 | Tocilizumab for the treatment of paraneoplastic inflammatory syndrome associated with angiomatoid fibrous histiocytoma |
| Q64987698 | Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. |
| Q55023313 | Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. |
| Q90711354 | Towards the era of precision medicine in metastatic colorectal cancer |
| Q128649288 | Trastuzumab deruxtecan in human epidermal growth factor receptor 2-positive breast cancer brain metastases: a systematic review and meta-analysis |
| Q57821469 | Tumor evolution in non-small-cell lung cancer |
| Q113874539 | Tumor immune-gene expression profiles and peripheral immune phenotypes associated with clinical outcomes of locally advanced pancreatic cancer following FOLFIRINOX |
| Q54330083 | Tumour and cellular distribution of activated forms of PR in breast cancers: a novel immunohistochemical analysis of a large clinical cohort. |
| Q91710496 | Tumour location and efficacy of first-line EGFR inhibitors in KRAS/RAS wild-type metastatic colorectal cancer: retrospective analyses of two phase II randomised Spanish TTD trials |
| Q55179038 | Tumour network in glioma. |
| Q55167238 | Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer. |
| Q28079391 | Twenty years of anti-HER2 therapy-associated cardiotoxicity |
| Q64280655 | Two-way traffic: aligning expectations with current realities in oncology. Mid-term ESMO Presidency considerations |
| Q90292007 | UNICANCER: French prospective cohort study of treatment-related chronic toxicity in women with localised breast cancer (CANTO) |
| Q54841530 | Umberto Veronesi 1925–2016: obituary. |
| Q100693326 | Understanding EGFR heterogeneity in lung cancer |
| Q28075291 | Unravelling signal escape through maintained EGFR activation in advanced non-small cell lung cancer (NSCLC): new treatment options |
| Q100749985 | Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location |
| Q28073290 | Update on clinical research and state of the art management of patients with advanced sarcomas and GIST |
| Q58694209 | Updated 5-year survival and exploratory T x N subset analyses of ACTS-CC trial: a randomised controlled trial of S-1 versus tegafur-uracil/leucovorin as adjuvant chemotherapy for stage III colon cancer |
| Q54982227 | Updated survival outcomes of NEJ005/TCOG0902: a randomised phase II study of concurrent versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer with sensitive EGFR mutations. |
| Q54493905 | Upper tract urothelial carcinoma: a different disease entity in terms of management. |
| Q113187008 | Utilizing phenotypic characteristics of metastatic brain tumors to improve the probability of detecting circulating tumor DNA from cerebrospinal fluid in non-small-cell lung cancer patients: development and validation of a prediction model in a pros |
| Q103799333 | Uveal melanoma-associated cancers revisited |
| Q102335574 | Validation of prognostic scoring systems for patients with metastatic renal cell carcinoma enrolled in phase I clinical trials |
| Q55119439 | Value of surgical resection and timing of therapy in patients with pancreatic cancer at high risk for positive margins. |
| Q91710503 | Variations in the management of diarrhoea induced by cancer therapy: results from an international, cross-sectional survey among European oncologists |
| Q90437242 | Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome |
| Q55689035 | Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. |
| Q113442438 | WHO-ESMO collaboration in cancer control: policies into action to save lives |
| Q91047165 | What is new on the horizon in melanoma brain metastasis? |
| Q55076093 | Where do they come from? A call for complete transparency regarding the origin of human tissues in research. |
| Q90156140 | Whole exome sequencing analysis of urine trans-renal tumour DNA in metastatic colorectal cancer patients |
| Q55649747 | Widespread rash in lung adenocarcinoma. |
| Q94568572 | Young patients with cancer and a digital social network: the voice beyond the clinic |
| Q98611241 | erbB in NSCLC as a molecular target: current evidences and future directions |